var title_f13_45_14032="Laceration from coral";
var content_f13_45_14032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laceration from coral",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These coral lacerations were sustained while surfing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Taylor KS, Zoltan TB, Suraj A. Medical illnesses and injuries encountered during surfing. Curr Sports Med Rep 2006; 5:262. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14032=[""].join("\n");
var outline_f13_45_14032=null;
var title_f13_45_14033="Ephedrine and theophylline: International drug information";
var content_f13_45_14033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ephedrine and theophylline: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2211186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Theophylline and Ephedrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2211187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Theophylline Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2211188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of chronic bronchial asthma, asthmatic bronchitis, and other bronchospastic disorders; prophylactically use to stop or decrease asthmatic attacks",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2211190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;25 kg (Tedral&reg;):",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     -1 regular-release tablet (containing ephedrine 24 mg and theophylline 130 mg) 3-4 times/day or at first sign of an asthma attack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 1-2 regular-release tablets (containing ephedrine 24 mg and theophylline 130 mg) 3-4 times/day or at first sign of an asthma attack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tedral&reg; SA: 1 tablet upon arising and 1 tablet 12 hours later, daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2211497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet (Tedral&reg;): Ephedrine hydrochloride 24 mg and theophylline monohydrate 130 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, sustained action (Tedral&reg; SA): Ephedrine hydrochloride 48 mg and theophylline monohydrate 198 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10462 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14033=[""].join("\n");
var outline_f13_45_14033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2211186\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2211187\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2211188\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2211190\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821072\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2211497\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_45_14034="Neck zones";
var content_f13_45_14034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Zones of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14034=[""].join("\n");
var outline_f13_45_14034=null;
var title_f13_45_14035="Subendocardial injury current with exercise";
var content_f13_45_14035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Subendocardial ischemia during exercise testing as viewed from a V5 electrode",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: At rest, a normal ECG results from the firing of hypothetical action potentials from subendocardial (Endo) and subepicardial (Epi) muscle cells. Panel B: A diastolic injury current from injured subendocardial cells causes TQ segment elevation (or \"pseudo\" ST depression). Panel C: Systolic and diastolic injury currents from injured subendocardial cells (panel C) causes TQ elevation and \"true\" ST depression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14035=[""].join("\n");
var outline_f13_45_14035=null;
var title_f13_45_14036="Alosetron: Patient drug information";
var content_f13_45_14036=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Alosetron: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8149?source=see_link\">",
"     see \"Alosetron: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12824192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotronex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad side effects have happened while taking this drug. Call your doctor right away if you have hard stools (constipation), new or worse belly pain, or blood in your stools. You must sign a contract with your doctor to get this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat irritable bowel syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to alosetron or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, hard stools (constipation), Crohn's disease, diseased arteries in the bowel, a large colon, hole in the GI (gastrointestinal) tract, bowel block, ischemic or ulcerative colitis, or very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to learn or follow the Patient-Physician contract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12232 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14036=[""].join("\n");
var outline_f13_45_14036=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824192\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028911\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028913\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028912\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028917\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028918\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028920\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028915\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028916\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028921\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028922\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8149?source=related_link\">",
"      Alosetron: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_45_14037="LCDD tubules EM";
var content_f13_45_14037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light chain deposition disease - electron micrograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph showing granular deposits (arrow) along the tubular basement membrane in light chain deposition disease. The appearance of these deposits is different from the fibrils seen in amyloidosis even though both types of deposits are composed of light chain fragments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14037=[""].join("\n");
var outline_f13_45_14037=null;
var title_f13_45_14038="Nalbuphine: Drug information";
var content_f13_45_14038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nalbuphine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/46/43747?source=see_link\">",
"    see \"Nalbuphine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/15/26869?source=see_link\">",
"    see \"Nalbuphine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Analgesic, Opioid Partial Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pain management:",
"     </b>",
"     I.M., I.V., SubQ: 10 mg/70 kg every 3-6 hours; maximum single dose in nonopioid-tolerant patients: 20 mg; maximum daily dose: 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Surgical anesthesia supplement:",
"     </b>",
"     I.V.: Induction: 0.3-3 mg/kg over 10-15 minutes;  maintenance doses of 0.25-0.5 mg/kg may be given as required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Opioid-induced pruritus (unlabeled use):",
"     </b>",
"     I.V. 2.5-5 mg; may repeat dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F199311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/15/26869?source=see_link\">",
"      see \"Nalbuphine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain management  (unlabeled use):",
"     </b>",
"     Children &ge;1 year: I.M., I.V., SubQ: 0.1-0.2 mg/kg every 3-4 hours as needed; maximum: 20 mg/dose and/or 160 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F199300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dose. Monitor.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F199301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 10 mg/mL (10 mL); 20 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 10 mg/mL (1 mL); 20 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F199278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.M., SubQ, or I.V.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F199329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, aztreonam, bivalirudin, cisatracurium, cladribine, dexmedetomidine, etoposide phosphate, fenoldopam, filgrastim, fludarabine, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, melphalan, oxaliplatin, paclitaxel, propofol, remifentanil, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, docetaxel, methotrexate, nafcillin, pemetrexed, piperacillin/tazobactam, sargramostim, sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, cimetidine, diphenhydramine, droperidol, glycopyrrolate, hydroxyzine, lidocaine, midazolam, prochlorperazine edisylate, ranitidine, scopolamine, trimethobenzamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, dimenhydrinate, ketorolac, pentobarbital.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Promethazine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate-to-severe pain; preoperative analgesia, postoperative and surgical anesthesia, and obstetrical analgesia during labor and delivery",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F3277917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opioid-induced pruritus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nubain may be confused with Navane&reg;, Nebcin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Sedation (36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (5%), headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (6%), xerostomia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Clamminess (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, agitation, allergic reaction, anaphylaxis, anaphylactoid reaction, anxiety, asthma, bitter taste, blurred vision, bradycardia, cardiac arrest, confusion, crying, delusion, depersonalization, depression, diaphoresis, dreams (abnormal), dyspepsia, dysphoria, dyspnea, euphoria, faintness, fever, floating sensation, flushing, gastrointestinal cramps, hallucinations, hostility, hypertension, hypotension,  injection site reactions (pain, swelling, redness, burning); laryngeal edema, loss of consciousness,  nervousness, numbness, pruritus, pulmonary edema, rash, respiratory depression, respiratory distress, restlessness, seizure, sensation of warmth/burning, somnolence, speech disorder, stridor, tachycardia, tingling, tremor, unreality, urinary urgency, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nalbuphine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with decreased renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Use with caution in pregnancy; close neonatal monitoring required when used in labor and delivery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F199290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F199283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe fetal bradycardia has been reported following use in labor/delivery. Fetal bradycardia may occur when administered earlier in pregnancy (not documented). Use only if clearly needed, with monitoring to detect and manage possible adverse fetal effects. Naloxone has been reported to reverse bradycardia. Newborn should be monitored for respiratory depression or bradycardia following nalbuphine use in labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nalbuphine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $1.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1 mL): $2.71",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F199272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain, respiratory and mental status, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Analin (PH);",
"     </li>",
"     <li>",
"      Azerty (FR);",
"     </li>",
"     <li>",
"      Bain (TW);",
"     </li>",
"     <li>",
"      Bufigen (MX);",
"     </li>",
"     <li>",
"      Intapan (MY);",
"     </li>",
"     <li>",
"      Nalbufina (UY);",
"     </li>",
"     <li>",
"      Nalbuphin OrPha (CH);",
"     </li>",
"     <li>",
"      Nalcryn SP (MX);",
"     </li>",
"     <li>",
"      Nalpain (DK, FI, PT, SE);",
"     </li>",
"     <li>",
"      Nubain (AE, AT, BF, BH, BJ, BR, CI, CY, CZ, DE, EE, EG, ET, GB, GH, GM, GN, GR, HN, HU, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PH, PK, PL, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nubaina (AR);",
"     </li>",
"     <li>",
"      Onfor (AR, PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agonist of kappa opiate receptors and partial antagonist of mu opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: SubQ, I.M.: &lt;15 minutes; I.V.: 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (&sim;7% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Health Care Policy and Research, &ldquo;Acute Pain Management in Infants, Children and Adolescents: Operative and Medical Procedures,\"",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1992,  46(2):469-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/1636563/pubmed\" id=\"1636563\" target=\"_blank\">",
"        1636563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen SE, Ratner EF, Kreitzman TR, et al, &ldquo;Nalbuphine is Better Than Naloxone for Treatment of Side Effects After Epidural Morphine,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1992, 75(5):747-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/1416128/pubmed\" id=\"1416128\" target=\"_blank\">",
"        1416128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Errick JK and Heel RC, &ldquo;Nalbuphine: A Preliminary Review of Its Pharmacological Properties and Therapeutic Efficacy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1983, 26(3):191-211.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/6137354/pubmed\" id=\"6137354\" target=\"_blank\">",
"        6137354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaillon P, Gardin ME, Lecocq B, et al, &ldquo;Pharmacokinetics of Nalbuphine in Infants, Young Healthy Volunteers, and Elderly Patients,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1989, 46(2):226-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/2758732/pubmed\" id=\"2758732\" target=\"_blank\">",
"        2758732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leikin JB, Ehrenpreis ED, Barkin RL, et al, &ldquo;Nalbuphine vs Meperidine in Sickle Cell Anemia,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1990, 24(7-8):781-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/2375146/pubmed\" id=\"2375146\" target=\"_blank\">",
"        2375146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoo YC, Chung HS, Kim IS, et al, &ldquo;Determination of Nalbuphine in Drug Abusers' Urine,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14038/abstract-text/7769781/pubmed\" id=\"7769781\" target=\"_blank\">",
"        7769781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9676 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14038=[""].join("\n");
var outline_f13_45_14038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199322\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199298\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199311\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199299\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199300\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199301\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199274\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199260\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199278\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199329\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199277\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3277917\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199331\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199320\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199281\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199264\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299737\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199269\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199290\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199270\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199283\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199303\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323450\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199272\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199284\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199263\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199280\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9676|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/46/43747?source=related_link\">",
"      Nalbuphine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/15/26869?source=related_link\">",
"      Nalbuphine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_45_14039="Anatomy and basic biomechanics of the wrist";
var content_f13_45_14039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anatomy and basic biomechanics of the wrist",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/45/14039/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/45/14039/contributors\">",
"     Blake Reid Boggess, DO, FAAFP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/45/14039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/45/14039/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/45/14039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/45/14039/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/45/14039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3736748\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wrist is a complex joint that serves as the link between the forearm and hand and is critical for many upper extremity movements. An understanding of wrist anatomy allows for appreciation of the biomechanics of wrist movement, which helps the clinician to understand injury patterns, perform an efficient history and physical examination, and improve diagnostic accuracy and treatment decisions.",
"   </p>",
"   <p>",
"    This topic will review the anatomy and biomechanics of the wrist. Approaches to the diagnosis of wrist pain and detailed discussions of specific wrist problems are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736755\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736763\">",
"    <span class=\"h2\">",
"     Orientation and terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic position of the wrist defines the palmar or volar surface as anterior and the dorsal surface as posterior (",
"    <a class=\"graphic graphic_figure graphicRef78359 \" href=\"UTD.htm?26/34/27172\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56302 \" href=\"UTD.htm?41/25/42386\">",
"     figure 2",
"    </a>",
"    ). The ulna is considered medial and the radius lateral. The wrist is defined as the distal aspect of the radius and ulna, the eight carpal bones, and their articulations with the proximal metacarpals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736770\">",
"    <span class=\"h2\">",
"     Carpal bones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carpal bones are divided into two rows: proximal and distal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51990 \" href=\"UTD.htm?4/46/4838\">",
"     figure 3",
"    </a>",
"    ). The proximal carpal row is composed of the scaphoid, lunate, triquetrum, and pisiform. The distal carpal row is comprised of the trapezium, trapezoid, capitate, and hamate.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The scaphoid",
"      <em>",
"       ,",
"      </em>",
"      also called the \"navicular,\" is the second largest carpal bone and was so named from the Greek word &lsquo;&lsquo;scaphe&rsquo;&rsquo; meaning &lsquo;&lsquo;dug-out, trough, or boat,&rsquo;&rsquo; because of its remote resemblance to a boat. It is shaped somewhat like a kidney bean and traverses the midcarpal joint. It has three named regions, including the proximal pole, the distal pole (tubercle), and the waist, which separates the two poles. Over 80 percent of its surface is covered with articular cartilage.",
"      <br/>",
"      <br/>",
"      Blood is supplied to the scaphoid by branches of the radial artery [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/1\">",
"       1",
"      </a>",
"      ]. The dorsal scaphoid branch typically enters the dorsal ridge at the level of the scaphoid waist and supplies the proximal 70 to 80 percent of the bone. The volar (or palmar) scaphoid branch of the radial artery enters the more distal tubercle and supplies the distal 20 to 30 percent of the bone. The blood supply to the proximal pole of the scaphoid can be disrupted by a fracture, which increases the risk of delayed union or nonunion (",
"      <a class=\"graphic graphic_figure graphicRef50525 \" href=\"UTD.htm?38/10/39075\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"       \"Scaphoid fractures\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The lunate",
"      <em>",
"       ,",
"      </em>",
"      named because of its crescent shape, is located between the scaphoid and the triquetrum. It is divided into a dorsal pole and a palmar pole. The lateral and medial surfaces are small and flat surfaces for articulation with the scaphoid and triquetrum, respectively. Blood supply to the lunate is variable, and may arise from palmar and dorsal nutrient vessels (80 percent) or palmar vessels alone (20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/2\">",
"       2",
"      </a>",
"      ]. The lunate is held within the proximal row by the scapholunate and lunotriquetral interosseous ligaments as well as the extrinsic radiocarpal ligaments (",
"      <a class=\"graphic graphic_figure graphicRef63301 \" href=\"UTD.htm?38/7/39030\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24531?source=see_link\">",
"       \"Lunate fractures\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The triquetrum",
"      <em>",
"      </em>",
"      is a small, pyramid-shaped bone that is largely covered in ligaments. The triquetrum articulates with three bones: the lunate, pisiform, and hamate. The lateral surface of the triquetrum is flat and articulates with the lunate. The distal end faces laterally forming the sinuous, concave facet that articulates with the hamate bone. The ventromedial facet that articulates with the pisiform bone is oval shaped. The proximal end of the triquetrum forms a smooth facet for articulation with the articular disc of the distal radioulnar joint.",
"     </li>",
"     <li>",
"      The pisiform bone, named because of its resemblance to a pea, can be considered a sesamoid bone of the flexor carpi ulnaris tendon. This tendon continues distally as the pisohamate ligament. There is a single, elevated, flat oval articular facet on the dorsal surface of the pisiform that engages the triquetrum.",
"     </li>",
"     <li>",
"      The trapezium, or greater multangular, is situated between the scaphoid and the base of the first metacarpal. It has a slightly concave proximal surface for articulation with the scaphoid, a flat facet medially for articulation with the trapezoid, and a saddle configuration distally for articulation with the first metacarpal.",
"     </li>",
"     <li>",
"      The trapezoid, or lesser multangular, is one of the smallest carpal bones, located between the trapezium and the capitate. All of its articular surfaces, for the trapezium, base of the second metacarpal, and scaphoid, are relatively flat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The capitate is the largest carpal bone, and is divided into three parts: the head, neck, and body. The head is hemispherical and entirely covered by articular cartilage with no ligamentous insertions. The neck is covered in periosteum and represents a narrowed transition between the head and the body. The body is large and covered completely on both the palmar and dorsal sides by ligament insertions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The hamate is named for the hook &ldquo;hamulus.&rdquo; It is a large bone and forms the ulnar border of the distal carpal row. The hamate is divided into proximal pole, hook, and body regions. The proximal pole is completely covered with articular cartilage, and the hook is completely covered with ligament attachments. The hook of the hamate projects from the volar surface approximately 1 to 2 cm distal and is radial to the pisiform. The body has two relatively flat distal facets that engage the bases of the fourth and fifth metacarpals, as well as a panhandled lateral surface that engages the capitate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14285490\">",
"    <span class=\"h2\">",
"     Metacarpals and carpometacarpal joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal metacarpals and the carpometacarpal joints are considered part of the wrist. The metacarpals are numbered by convention, with the thumb metacarpal being the first, the index finger metacarpal being the second, and so on. The carpometacarpal joints are the articulations between the distal row of carpals and the bases of the first through fifth metacarpals. Both the first and fifth carpometacarpal joints are saddle joints allowing primarily two degrees of freedom of movement. The second through fourth carpometacarpal joints are plane synovial joints allowing one degree of freedom of movement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736784\">",
"    <span class=\"h2\">",
"     Distal radius and ulna and major wrist articulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major articulations of the wrist include the distal radioulnar joint (DRUJ), the interface between the distal radius and the proximal row of carpal bones, and the interface between the proximal and distal rows of carpal bones.",
"   </p>",
"   <p>",
"    The DRUJ is an L-shaped, pivot or trochoid joint that allows for forearm and hand pronation and supination. The joint is at risk for both acute and chronic injury, including dorsal and volar dislocations, chronic instability, and degenerative joint disease. DRUJ function depends upon the integrity of the triangular fibrocartilage complex (TFCC) (",
"    <a class=\"graphic graphic_figure graphicRef63443 \" href=\"UTD.htm?15/39/15986\">",
"     figure 6",
"    </a>",
"    ), extensor carpi ulnaris, interosseous ligament, pronator quadratus, and associated forearm muscles.",
"   </p>",
"   <p>",
"    The articular surface of the distal radius is convex and forms an ellipsoidal joint with the proximal row of carpals, specifically the scaphoid, lunate, and triquetrum. The distal ulna, or ulnar head, articulates with a fibrocartilaginous disc that separates it from the medial carpals. Both the distal radius, which normally extends beyond the end of the ulna, and the distal ulna have palpable styloid processes, which are clinically important for the wrist examination and for evaluating wrist injury.",
"   </p>",
"   <p>",
"    Medially, the proximal carpal row consists of the triquetrum and pisiform. The triquetrum articulates with the TFCC proximally and the hamate distally. The distal ulna does not articulate directly with the carpal bones, but serves as an attachment for a number of the stabilizing ligaments that comprise the ulnar portion of the wrist. The TFCC interposes between the distal ulna and carpus, serving as both a force-transmitting and a stabilizing structure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distal carpal row articulates through the midcarpal joint with the proximal carpal row and distally with the metacarpal bases. The trapezium articulates with the distal pole of the scaphoid and the base of the first metacarpal. It plays an important role in thumb function and is vulnerable to trapeziometacarpal (ie, first carpometacarpal joint) osteoarthritis through repetitive use injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/4\">",
"     4",
"    </a>",
"    ]. The capitate articulates proximally with the lunate and distally with the base of the third metacarpal and sometimes the fourth metacarpal. The hamate articulates with the ulnar side of the capitate, as well as the fourth and fifth metacarpal bases distally and the triquetrum proximally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736791\">",
"    <span class=\"h2\">",
"     Wrist ligaments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ligaments of the wrist form a complex network of collagen fascicles that almost completely cover the carpal bones (",
"    <a class=\"graphic graphic_figure graphicRef63301 \" href=\"UTD.htm?38/7/39030\">",
"     figure 5",
"    </a>",
"    ). The majority of carpal ligaments are capsular. This means that the ligament resides within the layers of the joint capsule. Ligaments found entirely within the joint are defined as intra-articular ligaments. These ligaments have a composition similar to capsular ligaments but are surrounded entirely by a synovial lamina. Individual ligaments may show some variation in tissue composition. As an example, some include fibrocartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wrist ligaments can be grouped into distal radioulnar, palmar radiocarpal, dorsal radiocarpal, ulnocarpal, palmar midcarpal, dorsal midcarpal, and interosseous, depending upon the principal location of the fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/6\">",
"     6",
"    </a>",
"    ]. Generally, the ligament is named for its most prominent bony connections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10656759\">",
"    <span class=\"h3\">",
"     Triangular fibrocartilage complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triangular fibrocartilage complex (TFCC) is formed by the triangular fibrocartilage discus (TFC), the radioulnar ligaments (RUL), and the ulnocarpal ligaments (UCL) (",
"    <a class=\"graphic graphic_figure graphicRef63443 \" href=\"UTD.htm?15/39/15986\">",
"     figure 6",
"    </a>",
"    ). The TFC is an articular discus with a triangular shape and a biconcave body that lies on the pole of the distal ulna. The central portion of the TFC is thin and consists of chondroid fibrocartilage; this type of tissue is often seen in structures that bear compressive loads.",
"   </p>",
"   <p>",
"    The RULs are the principal stabilizers of the DRUJ. There are two RULs, the palmar and dorsal radioulnar ligaments. These ligaments arise from the medial border of the distal radius and insert on the ulna at two separate and distinct sites: the ulna styloid and the fovea.",
"   </p>",
"   <p>",
"    The UCLs consist of the ulnolunate and the ulnotriquetral ligaments. They originate from the ulnar styloid and insert into the carpal bones of the wrist: the ulnolunate ligament inserts into the lunate and the ulnotriquetral ligament into the triquetrum. These ligaments prevent dorsal migration of the distal ulna. They become tauter during supination as the ulnar styloid moves away from the carpal bones&rsquo; volar side [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TFCC performs several important functions in the wrist. Its most important function is to stabilize the distal radioulnar joint (DRUJ). In addition, the TFCC assists with distributing forces exerted upon the ulnar aspect of the wrist, while the TFC in particular helps to absorb compressive forces.",
"   </p>",
"   <p>",
"    Ulnar variance refers to the relative distance between the articular surfaces of the ulna and the radius. This distance influences the proportion of a load that is transmitted through the distal ulna. In neutral ulnar variance (articular surfaces are at the same level), approximately 20 percent of the load is transmitted through the ulna. With negative ulnar variance (ulnar articular surface is proximal to that of the radius), the load across the ulna and the TFCC diminishes. This decrease in force transmission also occurs during supination because the radius moves distally on the ulna during this movement. The load placed upon the ulna and the TFCC increases with positive ulnar variance and during wrist pronation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TFCC is at substantial risk for injury and degeneration because of its anatomic complexity and multiple functions. Chronic and excessive loading causes degenerative TFCC tears. Most acute traumatic TFCC injuries occur during a fall onto an outstretched hand. These injuries are caused by the substantial axial load placed upon the wrist while it is extended and pronated. A powerful dorsal rotation or distraction force exerted upon the wrist can also injure the TFCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736798\">",
"    <span class=\"h2\">",
"     Wrist tendons",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no intrinsic muscles of the wrist. All have their origins proximal to the wrist joint and insert at the hand, predominantly onto the metacarpals. An exception is the flexor carpi ulnaris, which inserts at the pisiform and fifth metacarpal base.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736805\">",
"    <span class=\"h3\">",
"     Wrist compartments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensor tendons are held in place by the extensor retinaculum (",
"    <a class=\"graphic graphic_figure graphicRef85859 \" href=\"UTD.htm?37/47/38647\">",
"     figure 7",
"    </a>",
"    ). As these tendons move over the posterior aspect of the wrist, they are protected within synovial tendon sheaths. These sheaths reduce friction as the extensor tendons traverse the osseous-fibrous tunnels of the wrist.",
"   </p>",
"   <p>",
"    The extensor tendons that traverse the wrist are contained within six compartments:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compartment 1 &ndash; Contains the abductor pollicis longus and the extensor pollicis brevis tendons (",
"      <a class=\"graphic graphic_figure graphicRef85861 \" href=\"UTD.htm?3/42/3745\">",
"       figure 8",
"      </a>",
"      ). These tendons lie within the radial border of the anatomical snuff box.",
"     </li>",
"     <li>",
"      Compartment 2 &ndash; Contains the extensor carpi radialis longus and extensor carpi radialis brevis tendons (",
"      <a class=\"graphic graphic_figure graphicRef85862 \" href=\"UTD.htm?21/20/21829\">",
"       figure 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Compartment 3 &ndash; Contains the extensor pollicis longus tendon, which passes medial to the dorsal tubercle (Lister&rsquo;s Tubercle) of the radius (",
"      <a class=\"graphic graphic_figure graphicRef85863 \" href=\"UTD.htm?29/21/30033\">",
"       figure 10",
"      </a>",
"      ). The extensor pollicis longus tendon attaches to the base of the distal phalanx of the thumb, forming the ulnar border of the anatomical snuff box (",
"      <a class=\"graphic graphic_picture graphicRef82858 \" href=\"UTD.htm?41/27/42419\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef82859 \" href=\"UTD.htm?35/44/36547\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Compartment 4 &ndash; Contains the extensor digitorum and extensor indicis tendons (",
"      <a class=\"graphic graphic_figure graphicRef85864 \" href=\"UTD.htm?25/32/26114\">",
"       figure 11",
"      </a>",
"      ). Proximally, the four tendons of the extensor digitorum join the tendon of the Extensor indicis to pass deep to the extensor retinaculum through the tendinous sheath of the extensor digitorum and extensor indicis. Then, on the dorsum of the hand, the tendons fan out as they run towards individual fingers.",
"     </li>",
"     <li>",
"      Compartment 5 &ndash; The extensor digiti minimi tendon travels through this compartment, posterior to the distal radioulnar joint (",
"      <a class=\"graphic graphic_figure graphicRef85865 \" href=\"UTD.htm?27/42/28322\">",
"       figure 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Compartment 6 &ndash; Contains the extensor carpi ulnaris tendon (",
"      <a class=\"graphic graphic_figure graphicRef85866 \" href=\"UTD.htm?5/37/5717\">",
"       figure 13",
"      </a>",
"      ). It runs in a groove between the ulnar head and its styloid process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736812\">",
"    <span class=\"h3\">",
"     Carpal tunnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total of nine flexor tendons pass through the carpal tunnel (",
"    <a class=\"graphic graphic_figure graphicRef53265 \" href=\"UTD.htm?18/45/19158\">",
"     figure 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68934 \" href=\"UTD.htm?34/30/35302\">",
"     figure 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81015 \" href=\"UTD.htm?0/60/960\">",
"     image 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flexor digitorum profundus (four tendons)",
"     </li>",
"     <li>",
"      Flexor digitorum superficialis (four tendons)",
"     </li>",
"     <li>",
"      Flexor pollicis longus (one tendon)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The median nerve courses between tendons of flexor digitorum profundus and flexor digitorum superficialis. There are multiple naturally occurring anomalies of the median nerve. The recurrent branch of the median nerve innervates the thenar muscles.&nbsp;Bifurcation of the median nerve typically occurs after the nerve exits the carpal tunnel. However, in approximately 5 to 10 percent of individuals, the median nerve bifurcates more proximally in the carpal tunnel, wrist, or forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The carpal bones form an arch that is convex on the dorsal side of the hand and concave on the palmar side (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81015 \" href=\"UTD.htm?0/60/960\">",
"     image 2",
"    </a>",
"    ). The groove on the palmar side is called the sulcus carpi and is covered by a sheath of tough connective tissue called the flexor retinaculum. This is what forms the carpal tunnel. The flexor retinaculum is attached radially to the scaphoid tubercle and the ridge of trapezium, and on the ulnar side to the pisiform and hook of hamate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736819\">",
"    <span class=\"h3\">",
"     Guyon's canal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also known as the &ldquo;ulnar canal&rdquo; or &ldquo;ulnar tunnel,&rdquo; Guyon&rsquo;s canal is the space between the pisiform bone and the hamate bone through which the ulnar artery and the ulnar nerve travel into the hand (",
"    <a class=\"graphic graphic_figure graphicRef57601 \" href=\"UTD.htm?15/0/15364\">",
"     figure 16",
"    </a>",
"    ). Entrapment of the ulnar nerve at the ulnar canal can result in ulnar neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736826\">",
"    <span class=\"h2\">",
"     Neurovascular anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innervation of structures within the wrist joint corresponds to the innervation of the overlying skin. Each superficial nerve sends articular branches to the wrist joint capsule that enter the ligamentous or capsular tissue. The nerves of the wrist joint capsule are the superficial radial nerve, the dorsal sensory branch of the ulnar nerve, the deep branch of the ulnar nerve, the lateral antebrachial cutaneous nerve, the anterior interosseous nerve, and the posterior interosseous nerve (",
"    <a class=\"graphic graphic_figure graphicRef57601 \" href=\"UTD.htm?15/0/15364\">",
"     figure 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70720 \" href=\"UTD.htm?37/44/38593\">",
"     figure 17",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76075 \" href=\"UTD.htm?23/56/24448\">",
"     figure 18",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blood supply of the wrist is provided by branches of the radial artery, ulnar artery, and the interosseous arterial system (",
"    <a class=\"graphic graphic_figure graphicRef74598 \" href=\"UTD.htm?32/4/32840\">",
"     figure 19",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/13\">",
"     13",
"    </a>",
"    ]. There are many anastomotic pathways, including the longitudinal and transverse, and the palmar and dorsal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/14\">",
"     14",
"    </a>",
"    ]. Typically, three dorsal arches and three palmar arches traverse the region of the carpals.",
"   </p>",
"   <p>",
"    Of note, the scaphoid and the lunate have vulnerable blood supplies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/15\">",
"     15",
"    </a>",
"    ]. The scaphoid gets its blood supply from nutrient vessels entering at the distal pole and the waist of the scaphoid. This means that the proximal pole is dependent on continuity with the waist of the scaphoid for a blood supply. Therefore, the proximal pole of the scaphoid is at risk of osteonecrosis following fractures proximal to the waist of the scaphoid (",
"    <a class=\"graphic graphic_figure graphicRef50525 \" href=\"UTD.htm?38/10/39075\">",
"     figure 4",
"    </a>",
"    ). The lunate generally receives nutrient vessels from the dorsal and palmar ligamentous attachments, but these vessels have variable intraosseous anastomotic patterns. When the vascular supply to the lunate is compromised, such as following a traumatic injury, the bone may develop avascular necrosis (Kienbock&rsquo;s disease), especially the proximal pole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24531?source=see_link\">",
"     \"Lunate fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41143608\">",
"    <span class=\"h1\">",
"     BASIC BIOMECHANICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14285782\">",
"    <span class=\"h2\">",
"     Wrist structure and positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structurally, the hand is a linked system of bony segments, arranged in a series of longitudinal and transverse arches. An arch better withstands external forces than most other structures and helps distribute force across the entire structure rather than to any one carpal bone.",
"   </p>",
"   <p>",
"    There are basically two transverse arches: the proximal transverse arch, formed by the carpal bones, and the distal arch, formed by the metacarpal heads. The longitudinal arches consist of the bones of the five digital rays. The proximal part of the longitudinal arches and the proximal transverse arch converge at the carpal bones. The carpal bones stabilize the longitudinal arches and their related structures, and are central to the function of the hand.",
"   </p>",
"   <p>",
"    The dominant wrist position during daily activities is dorsiflexion with radial deviation, which is seen in writing, typing, lifting, and holding. The ability to maintain the carpals in this position relies on the bony contour of the distal radius and radial carpus. The broad distal portion of the radius causes the overlying tendons to protrude outwards, increasing the distance between these tendons and their centers of motion, thereby creating greater force moments. These larger force moments allow the wrist to be more easily maintained or moved into the position of function.",
"   </p>",
"   <p>",
"    The dominant pattern of wrist motion is from the position of dorsiflexion with radial deviation into palmar flexion with ulnar deviation, the so-called &lsquo;&lsquo;dart-throwing&rsquo;&rsquo; motion. Both the bony contours and the relationship between the extensor and flexor tendons and the carpal bones make this motion possible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3736833\">",
"    <span class=\"h2\">",
"     Wrist motion",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flexion &ndash; The primary wrist flexors are the flexor carpi radialis (FCR) and the flexor carpi ulnaris (FCU), with assistance from the palmaris longus and abductor pollicis longus. The digital flexors are involved only when the fingers are held in extension [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14039/abstract/17\">",
"       17",
"      </a>",
"      ]. The FCR and FCU originate from the medial epicondyle of the humerus at the elbow, and insert at the volar base of the second, third, and fifth metacarpals respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extension &ndash; Wrist extension occurs when the extensor carpi radialis longus (ECRL) and brevis (ECRB) and extensor carpi ulnaris (ECU) contract. The ECRL originates at the lateral supracondylar ridge of the humerus and the ERCB and ECU muscles originate at the lateral epicondyle of the humerus. The ECRL, ECRB, and ECU insert at the dorsal base of the second, third, and fifth metacarpals, respectively. The thumb and digital extensors can also participate in extension when the fist is clenched.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ulnar deviation &ndash; Ulnar deviation is performed through contraction of the flexor and extensor ulnaris muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radial Deviation &ndash; Radial deviation is performed through contraction of the ECRL and FCR muscles. The ECRB and thumb extensors and abductors may contribute as well.",
"     </li>",
"     <li>",
"      Pronation and supination &ndash; These movements do not actually take place at the wrist joint but occur in the forearm. Pronation is performed by contraction of the pronator teres and pronator quadratus muscles, with some contribution from the FCR when the wrist is flexed. Supination is performed by contraction of the supinator and biceps brachii muscles.",
"     </li>",
"     <li>",
"      Circumduction &ndash; Circumduction is the joint action which produces a circular, conical movement of the limb extending from that joint. The wrist can produce this motion by combining palmar flexion and dorsiflexion with radial and ulnar deviation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41143713\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anatomic position of the wrist defines the palmar or volar surface as anterior and the dorsal surface as posterior (",
"      <a class=\"graphic graphic_figure graphicRef78359 \" href=\"UTD.htm?26/34/27172\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56302 \" href=\"UTD.htm?41/25/42386\">",
"       figure 2",
"      </a>",
"      ). The ulna is considered medial and the radius lateral. The wrist is defined as the distal aspect of the radius and ulna, the eight carpal bones, and their articulations with the proximal metacarpals.",
"     </li>",
"     <li>",
"      The carpal bones are divided into two rows: proximal and distal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef51990 \" href=\"UTD.htm?4/46/4838\">",
"       figure 3",
"      </a>",
"      ). The proximal carpal row is composed of the scaphoid, lunate, triquetrum, and pisiform. The distal carpal row is comprised of the trapezium, trapezoid, capitate, and hamate. (See",
"      <a class=\"local\" href=\"#H3736770\">",
"       'Carpal bones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major articulations of the wrist include the distal radioulnar joint (DRUJ), the interface between the distal radius and the proximal row of carpal bones, the interface between the proximal and distal rows of carpal bones, and the interface between the distal row of carpal bones and the metacarpals. (See",
"      <a class=\"local\" href=\"#H14285490\">",
"       'Metacarpals and carpometacarpal joints'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3736784\">",
"       'Distal radius and ulna and major wrist articulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ligaments of the wrist form a complex network of collagen fascicles that almost completely cover the carpal bones (",
"      <a class=\"graphic graphic_figure graphicRef63301 \" href=\"UTD.htm?38/7/39030\">",
"       figure 5",
"      </a>",
"      ). The triangular fibrocartilage complex performs several important functions in the wrist, most importantly stabilizing the DRUJ. (See",
"      <a class=\"local\" href=\"#H3736791\">",
"       'Wrist ligaments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no intrinsic muscles of the wrist. The extensor tendons that traverse the wrist are held in place by the extensor retinaculum. Nine flexor tendons pass through the carpal tunnel, along with the median nerve (",
"      <a class=\"graphic graphic_figure graphicRef53265 \" href=\"UTD.htm?18/45/19158\">",
"       figure 14",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef68934 \" href=\"UTD.htm?34/30/35302\">",
"       figure 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81015 \" href=\"UTD.htm?0/60/960\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3736798\">",
"       'Wrist tendons'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The innervation of structures within the wrist joint corresponds to the innervation of the overlying skin. The blood supply of the wrist is provided by branches of the radial artery, ulnar artery, and the interosseous arterial system (",
"      <a class=\"graphic graphic_figure graphicRef74598 \" href=\"UTD.htm?32/4/32840\">",
"       figure 19",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3736826\">",
"       'Neurovascular anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The basic structure and motion of the wrist is reviewed in the text. (See",
"      <a class=\"local\" href=\"#H41143608\">",
"       'Basic biomechanics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/1\">",
"      Rettig AC. Management of acute scaphoid fractures. Hand Clin 2000; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/2\">",
"      Freedman DM, Botte MJ, Gelberman RH. Vascularity of the carpus. Clin Orthop Relat Res 2001; :47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/3\">",
"      Garcia-Elias M. Soft-tissue anatomy and relationships about the distal ulna. Hand Clin 1998; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/4\">",
"      Zancolli EA. The trapeziometacarpal joint. Tenotomy of the accessory tendons in early osteoarthritis. Hand Clin 2001; 17:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/5\">",
"      Berger RA, Blair WF. The radioscapholunate ligament: a gross and histologic description. Anat Rec 1984; 210:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/6\">",
"      Taleisnik J. The ligaments of the wrist. J Hand Surg Am 1976; 1:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/7\">",
"      Ishii S, Palmer AK, Werner FW, et al. An anatomic study of the ligamentous structure of the triangular fibrocartilage complex. J Hand Surg Am 1998; 23:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/8\">",
"      Palmer AK, Werner FW. Biomechanics of the distal radioulnar joint. Clin Orthop Relat Res 1984; :26.",
"     </a>",
"    </li>",
"    <li>",
"     Rolls SC, Evans KD. Songraphic representation of bifid median nerve and persistent median artery. Journal of Diagnostic Medical Sonography 2011; 27:89. file://jdm.sagepub.com/content/27/2/89.abstract (Accessed on July 16, 2012).",
"    </li>",
"    <li>",
"     Schueknke M, Schulte E, Schumacher U. The Carpal Tunnell. In: General Anatomy and the Musculoskeletal System, Lamperti ED, Ross RM.  (Eds), Thieme, New York 2006. p.354.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/11\">",
"      Shea JD, McClain EJ. Ulnar-nerve compression syndromes at and below the wrist. J Bone Joint Surg Am 1969; 51:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/12\">",
"      Fukumoto K, Kojima T, Kinoshita Y, Koda M. An anatomic study of the innervation of the wrist joint and Wilhelm's technique for denervation. J Hand Surg Am 1993; 18:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/13\">",
"      Gelberman RH, Panagis JS, Taleisnik J, Baumgaertner M. The arterial anatomy of the human carpus. Part I: The extraosseous vascularity. J Hand Surg Am 1983; 8:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/14\">",
"      Sheetz KK, Bishop AT, Berger RA. The arterial blood supply of the distal radius and ulna and its potential use in vascularized pedicled bone grafts. J Hand Surg Am 1995; 20:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/15\">",
"      Panagis JS, Gelberman RH, Taleisnik J, Baumgaertner M. The arterial anatomy of the human carpus. Part II: The intraosseous vascularity. J Hand Surg Am 1983; 8:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14039/abstract/16\">",
"      Tang JB. General concepts of wrist biomechanics and a view from other species. J Hand Surg Eur Vol 2008; 33:519.",
"     </a>",
"    </li>",
"    <li>",
"     Jenkins DB. Radioulnar and wrist movements. In: Hollinshead's Functional Anatomy of the Limbs and Back, WB Saunders, Philadelphia 2002. p.171.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83994 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14039=[""].join("\n");
var outline_f13_45_14039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41143713\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3736748\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3736755\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3736763\">",
"      Orientation and terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3736770\">",
"      Carpal bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14285490\">",
"      Metacarpals and carpometacarpal joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3736784\">",
"      Distal radius and ulna and major wrist articulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3736791\">",
"      Wrist ligaments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10656759\">",
"      - Triangular fibrocartilage complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3736798\">",
"      Wrist tendons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3736805\">",
"      - Wrist compartments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3736812\">",
"      - Carpal tunnel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3736819\">",
"      - Guyon's canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3736826\">",
"      Neurovascular anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41143608\">",
"      BASIC BIOMECHANICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14285782\">",
"      Wrist structure and positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3736833\">",
"      Wrist motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41143713\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/83994\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83994|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/16/38146\" title=\"diagnostic image 1\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/60/960\" title=\"diagnostic image 2\">",
"      Carpal tunnel view of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83994|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/34/27172\" title=\"figure 1\">",
"      Anatomy wrist dorsal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42386\" title=\"figure 2\">",
"      Anatomy wrist radial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4838\" title=\"figure 3\">",
"      Wrist hand bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/10/39075\" title=\"figure 4\">",
"      Scaphoid arterial supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39030\" title=\"figure 5\">",
"      Wrist ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/39/15986\" title=\"figure 6\">",
"      Anatomy of the triangular fibrocartilage complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/47/38647\" title=\"figure 7\">",
"      Extensor tendons traversing wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/42/3745\" title=\"figure 8\">",
"      Ultrasound of first extensor compartment wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/20/21829\" title=\"figure 9\">",
"      Ultrasound of second extensor compartment wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/21/30033\" title=\"figure 10\">",
"      Ultrasound of third extensor compartment wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/32/26114\" title=\"figure 11\">",
"      Ultrasound of fourth extensor compartment wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/42/28322\" title=\"figure 12\">",
"      Ultrasound of fifth extensor compartment wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/37/5717\" title=\"figure 13\">",
"      Ultrasound of sixth extensor compartment wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/45/19158\" title=\"figure 14\">",
"      Cross section of wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/30/35302\" title=\"figure 15\">",
"      View of the carpal tunnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/0/15364\" title=\"figure 16\">",
"      Major branches of the ulnar nerve at the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/44/38593\" title=\"figure 17\">",
"      Median sensory territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/56/24448\" title=\"figure 18\">",
"      Cutaneous sensory distribution of the ulnar nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/4/32840\" title=\"figure 19\">",
"      Hand and wrist anatomy palmar view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83994|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/27/42419\" title=\"picture 1\">",
"      Wrist anatomic snuffbox location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/44/36547\" title=\"picture 2\">",
"      Palpation of scaphoid in anatomic snuffbox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24531?source=related_link\">",
"      Lunate fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_45_14040="Hydroa vacciniforme 2";
var content_f13_45_14040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68305%7EDERM%2F54500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68305%7EDERM%2F54500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hydroa vacciniforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and crusts are seen on the forearm of a 10-year-old boy with hydroa vacciniforme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hydroa vacciniforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scars and crusted papules are present on the face. This 10-year-old boy had a history of recurrent blisters in sun exposed areas that healed with depressed vaccination-like scars.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14040=[""].join("\n");
var outline_f13_45_14040=null;
var title_f13_45_14041="Bursitis: An overview of clinical manifestations, diagnosis, and management";
var content_f13_45_14041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bursitis: An overview of clinical manifestations, diagnosis, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/45/14041/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/45/14041/contributors\">",
"     Robert P Sheon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/45/14041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/45/14041/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/45/14041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/45/14041/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/45/14041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bursitis is an inflammation or degeneration of the sac-like structures that form in utero to protect the soft tissues from underlying bony prominences [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/1\">",
"     1",
"    </a>",
"    ]. Bursitis may result from a local insult or be a manifestation of a systemic disease. Examples of the latter include rheumatoid arthritis, tophaceous gout, and sepsis.",
"   </p>",
"   <p>",
"    The most common locations of bursitis are the subdeltoid, olecranon, ischial, trochanteric, and prepatellar bursae. Inflammation or degeneration at these sites is usually the result of a repetitive movement injury. Adjacent tenosynovitis and calcium apatite deposition disease commonly coexist.",
"   </p>",
"   <p>",
"    When bursitis occurs with repetitive movement disorders, pathologic features of inflammation are often limited to a portion of the bursa. Typical findings are those of degeneration and regeneration. As an example, in a study of 63 patients undergoing surgery for rotator cuff tears, impingement, or calcific tendinitis, findings at surgery included the deposition of new collagen and expression of type III collagen perivascularly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the overall approach to the diagnosis and management of bursitis. Specific bursitis presentations will also be explored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of bursitis is usually suspected on clinical grounds. Bursitis typically has the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain on motion and at rest",
"     </li>",
"     <li>",
"      Occasional regional loss of active movement",
"     </li>",
"     <li>",
"      Swelling when bursitis occurs close to the body surface (eg, bunion, prepatellar or olecranon bursitis)",
"     </li>",
"     <li>",
"      Local tenderness at a site where a bursa is usually present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, bursitis is only one of many possible causes of localized or regional pain, reduced active range of motion and preserved passive range of motion; this finding is also consistent with tendinitis or muscle injury. By contrast, a decrease in both active and passive range of motion is more typical of synovitis, soft tissue contracture, or a structural abnormality of the joint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history should include an inquiry about acute trauma or repetitive injury to the painful area, occupation and avocational activities that involve the affected region (eg, overhead lifting or forceful pulling in the case of shoulder pain, bicycling or prolonged sitting on a hard surface in the case of ischial pain, repeated kneeling or possible skin perforating injury or skin abrasion for those with prepatellar pain).",
"   </p>",
"   <p>",
"    In the absence of a history suggesting acute trauma or repetitive bursal injury, a thorough past medical history and review of systems is needed to assess for preexisting diseases that could cause bursitis and for the presence of any systemic disorder that could cause or mimic bursitis. A history suggestive of a current or recent bacterial infection, or the finding of fever, increases the likelihood of septic bursitis.",
"   </p>",
"   <p>",
"    In the absence of features in the medical history suggestive of an infectious or systemic disease, the physical examination is typically focused on the painful region. Detailed descriptions of the physical examination of the shoulder, hip, and knee are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further diagnostic testing may be necessary if infection or crystal disease is suspected based upon the initial medical history and examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=see_link\">",
"     \"Overview of soft tissue rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of superficial bursae (eg, olecranon, prepatellar, bunion), if signs of inflammation are present and an effusion is noted within the bursa, aspiration and bursal fluid examination are used to exclude infection and assess for a crystal-associated disorder (eg, gout or pseudogout).",
"   </p>",
"   <p>",
"    Patients with deep bursal inflammation (eg, iliopsoas, subacromial, trochanteric) and with other risk factors for, or clinical features suggesting, infection (eg, wound or other infection, bacteremia, fever, peripheral blood leukocytosis) may need imaging studies to assess for a bursal effusion, and to guide attempts at aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bursal fluid aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an inflamed superficial bursa has accumulated fluid that is detectable by palpation we suggest that the effusion be aspirated using a 16 or 18 gauge needle. Bursal fluid should be sent the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram stain and culture &mdash; If there is a sufficient amount of fluid, inoculation into blood culture media is recommended as liquid media increase the sensitivity of bacterial culture when compared with plating fluid directly onto solid media [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cell count and differential &mdash; Leukocytosis in bursal fluid may be substantially less intense in bursitis due to infectious and systemic inflammatory disorders than the elevations typically noted in joints affected by the same diseases. This is particularly important in the case of septic bursitis (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Septic bursitis'",
"      </a>",
"      below) in which, in one study, 8 of 13 patients with culture-proven septic bursitis had bursal fluid leukocyte counts less than",
"      <span class=\"nowrap\">",
"       20,000/mm3",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/4\">",
"       4",
"      </a>",
"      ]. In contrast only 1 of 18 patients with septic arthritis had synovial fluid nucleated cell counts less than that threshold. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .) A bursal fluid white cell count of more than",
"      <span class=\"nowrap\">",
"       1000/mm3",
"      </span>",
"      is suggestive of inflammation from infection, rheumatoid arthritis, or gout.",
"     </li>",
"     <li>",
"      Crystal search and analysis &mdash; Crystal identification utilizing compensated polarized microscopy is especially important if the patient has had a history of gout (particularly if inflammation persists despite therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/5\">",
"       5",
"      </a>",
"      ]), pseudogout, or recurrent olecranon bursitis. An experienced clinician or technician is recommended to assess for the presence of crystals and, if present, to classify them on the basis of their shape and birefringence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are typically",
"    <strong>",
"     not",
"    </strong>",
"    helpful in the setting of an acute superficial (eg, olecranon or prepatellar) bursitis. However, when superficial bursitis is of traumatic origin, foreign body penetration may be revealed by radiologic soft tissue techniques (eg, xerography or plain films) or by magnetic resonance imaging (MRI). In addition, MRI may aid in defining the extent of a soft tissue infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with inflammation of deep bursae (eg, subacromial, iliopsoas, trochanteric, or anserine) may have had plain film radiographs performed to exclude osseous causes of pain in the shoulder, hip, or knee, respectively. Calcific deposits of various sizes and shapes may be noted in association with clinically evident bursitis. Soft tissue calcification may be due to deposition of crystals of hydroxyapatite, basic calcium phosphate, or CPPD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Calcium-containing deposits may also be seen in tophaceous gout. Radiographically apparent calcific deposits may also be indicative of CPPD disease (which may also cause chondrocalcinosis) or gout.",
"   </p>",
"   <p>",
"    If septic bursitis of a deep bursa is suspected, imaging with CT or ultrasonography may be required to guide needle aspiration of the bursa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis of bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the source of pain and tenderness has been localized to a bursa and, if appropriate, bursal fluid has been examined, the cause of bursitis may be apparent. As mentioned earlier, common causes of bursitis include: infection, acute and repetitive trauma, crystal diseases, and bleeding. Inflammation of the skin and soft tissues adjacent to the bursa may be due to concomitant cellulitis in the case of a septic bursitis, or sterile inflammation in the case of tophaceous gout. Severe peribursal inflammation may limit joint motion and mimic acute monoarthritis. Thus, the differential diagnosis of acute bursitis includes many of the same disorders that are considered in the differential of acute monoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Septic bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic bursitis typically presents with peribursal erythema and warmth, often in the setting of diabetes, alcoholism, or immunosuppression. When the prepatellar or olecranon bursae are involved, abrasion or puncture of the overlying skin may be apparent. Septic deep bursal infection is uncommon but may occur, presumably due to hematogenous seeding or a contiguous site of infection. Bursal fluid in cases of septic bursitis is inflammatory, may have organisms noted on Gram stain, and is positive when cultured for bacteria, fungi, or mycobacteria. A more detailed discussion of the clinical manifestations, diagnosis, and treatment of septic bursitis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33256?source=see_link\">",
"     \"Septic bursitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gout and pseudogout are generally excluded as causes of bursitis based on the absence of crystals in the bursal fluid when examined using compensated polarized microscopy. Patients with crystal-induced bursitis should be investigated for underlying metabolic or hematologic diseases causing hyperuricemia (eg, lead intoxication, renal failure, hemolytic anemia, myeloproliferative disorders, or those that predispose to calcium pyrophosphate dihydrate (CPPD) crystal deposition (eg, hyperparathyroidism or hemochromatosis)). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with rheumatoid arthritis and bursitis due to rheumatoid disease typically have preexisting polyarthritis. Bursae in patients with rheumatoid arthritis are not usually the sole site of a flare of active rheumatoid disease. Thus, acute bursitis in such a patient should be considered to be septic bursitis until proven otherwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of nonseptic bursitis should include patient education and relief of the acute symptoms of inflammation. Nonsteroidal antiinflammatory drugs (NSAIDs) are generally used initially and glucocorticoid injections are reserved for patients who do not respond to antiinflammatory doses of NSAIDs. Surgical excision of the bursa is reserved for those with frequent relapses and those who are unresponsive to conservative treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;General information on bursitis for patients is presented separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"     \"Patient information: Bursitis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should be educated in the recognition of aggravating factors such as direct pressure on the elbows (eg, pushing up with elbows when arising from bed), knees (eg, kneeling), or greater trochanter (eg, lying on the affected side). Obesity, compression injury, or other minor local trauma may be additional factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of the elbows to arise from bed can be eliminated with a rope attached to the foot of the bed that is brought forward over the bed covers and used to pull up.",
"     </li>",
"     <li>",
"      Carrying heavy objects or repeatedly elevating the arm may lead to subacromial (subdeltoid) bursitis. When possible, patients should use both arms or pull heavy loads on wheels.",
"     </li>",
"     <li>",
"      Arising from a position of lumbar spine flexion (back bent forward) while the knees are kept straight requires a lever action of the glutei; this is perhaps the most common cause for gluteal strain, which in turn may predispose to trochanteric bursitis. These patients must learn to bend their knees before bending their backs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Joint protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint protection advice should be given to the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37508?source=see_link\">",
"     \"Joint protection program for the upper limb\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=see_link\">",
"     \"Joint protection program for the lower limb\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with bursitis in the medial aspect of the knee should sleep with a small cushion placed between the thighs so that the opposite knee does not rest upon the medial aspect of the involved knee.",
"     </li>",
"     <li>",
"      Use of kneeling pads is important for miners, carpet layers, and others whose daily activities predispose them to prepatellar bursitis.",
"     </li>",
"     <li>",
"      Patients with Achilles region bursitis may benefit from cutting a \"V\" groove into the back of an old shoe, or by inserting a thick heel pad to raise up the heel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pain relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ice, heat, and rest should be recommended until acute pain has subsided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs, either selective cyclooxygenase 2 inhibitors (coxibs) or nonselective agents, are effective in treating episodes of nonseptic bursitis. This was illustrated in a study that randomly assigned 306 patients with acute subacromial bursitis or shoulder tendinitis to receive celecoxib (400 mg once followed by 200 mg twice daily for 14 days),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (500 mg twice daily for 14 days), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/9\">",
"     9",
"    </a>",
"    ]. Both celecoxib and naproxen groups had significantly greater improvement in shoulder pain at rest at the end of one week than did those receiving placebo. Resolution usually occurs within a few days to weeks if the precipitating event is removed.",
"   </p>",
"   <p>",
"    We recommend regular daily use of a nonselective NSAID, such as indomethacin (75 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (500 mg twice daily) for several days, as initial treatment for acute, nonseptic bursitis. For patients at increased risk of gastroduodenal damage from an NSAID (eg, those with prior ulcer disease, gastrointestinal bleeding, or currently receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or other glucocorticoid, or those receiving anticoagulants) the clinician may recommend a coxib or concurrent prophylactic use of a proton pump inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is prudent to avoid use of NSAIDs and coxibs in patients with known coronary artery or cerebrovascular disease, or those with multiple risk factors for cardiovascular disease, those with renal disease, and edematous states due to the increased risk of adverse cardiovascular side effects",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the risk of acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Glucocorticoid injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the efficacy and safety of bursal injection of glucocorticoids from well-designed randomized and controlled clinical trials. Injections appear to be superior to NSAIDs in speeding recovery from, and preventing recurrences of, olecranon bursitis; subacromial glucocorticoid injections may be superior to placebo for pain due to subacromial bursitis or tendinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid injection was significantly more effective than a course of an oral NSAID in preventing recurrence of olecranon bursitis. This was illustrated in a study that randomly assigned 42 patients with nonseptic bursitis to one of four groups, two of the four groups received a single injection (20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      acetate) and the other two groups received no injection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/10\">",
"       10",
"      </a>",
"      ]. Patients were also randomly assigned to receive an oral NSAID (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       gm/day",
"      </span>",
"      for 10 days) or placebo. Patients who received an intrabursal injection of methylprednisolone had more rapid resolution of bursal swelling, and required fewer bursal aspirations over six months of study than those who did not receive a steroid injection whether an NSAID was taken or not.",
"     </li>",
"     <li>",
"      A 2003 meta-analysis of 26 clinical trials comparing subacromial injections, placebo, and NSAID treatments for shoulder pain ascribed to rotator cuff tendinitis, concluded that steroid injections were significantly more effective in relieving pain than placebo but were not more effective than NSAIDs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link&amp;anchor=H24#H24\">",
"       \"Rotator cuff tendinopathy\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with nonseptic bursitis that is not responsive to more conservative treatment, we suggest injection of a long-acting glucocorticoid mixed with an equal amount by volume of 1 percent lidocaine hydrochloride to provide pain relief and reduce the likelihood of recurrence. Of the parenteral glucocorticoid preparations, we suggest use of injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    if available. Typical doses are 40 mg for a large bursa (eg, subacromial or trochanteric) or 10 mg for a smaller bursa (eg, anserine or ischial). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    hexacetonide is another commonly used preparation. The author prefers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    to triamcinolone hexacetonide because of clinical experience suggesting an increased frequency of menstrual irregularity in premenopausal women, vaginal spotting in postmenopausal women, and of subcutaneous fat atrophy with triamcinolone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     lidocaine/steroid",
"    </span>",
"    mixture will flocculate and cause a cloudy appearance within the syringe. Using the shortest needle that can reach the required depth, the needle should be used as a probe. The patient should apply ice for 10 to 20 minutes after the injection. Injection should not be repeated within six to eight weeks.",
"   </p>",
"   <p>",
"    We suggest limiting the number of injections for the same problem to no more than two; if relief is not long lasting, other strategies, including surgery, should be considered. Function may be resumed when pain and signs of inflammation have subsided, often within a few days. However, if a tendon sheath is injected at the same time, activity should be curtailed for two weeks.",
"   </p>",
"   <p>",
"    Intrabursal steroid injection may also be used as initial therapy rather than a therapeutic trial of an NSAID when septic bursitis is estimated to be very unlikely and patients have one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relative or absolute contraindication to use of NSAID or coxibs",
"     </li>",
"     <li>",
"      Visible inflammation is present or night pain is severe",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SPECIFIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual types of bursitis have specific issues with regard to diagnosis and management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Subacromial bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subacromial bursa separates the bony acromion process of the scapula from the supraspinatus muscle and tendon (",
"    <a class=\"graphic graphic_figure graphicRef81764 \" href=\"UTD.htm?32/20/33093\">",
"     figure 1",
"    </a>",
"    ). Pain due to subacromial bursitis is typically present at rest and with use and is referred to the insertion of the deltoid muscle about four inches down the outer arm. Pain may be severe, interrupt sleep, and prevent any active movement. Passive arm movement is often restricted in abduction only.",
"   </p>",
"   <p>",
"    Subacromial bursitis may result from adjacent inflammation of the supraspinatus tendon, and can occur in association with rotator cuff tears, an impingement syndrome, or a systemic disorder such as polymyalgia rheumatica in which there is usually bilateral involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a rotator cuff tear is suggested by the presence of weakness when muscle strength is tested. Differentiating rotator cuff tear, rotator cuff tendinitis, and subacromial bursitis on the basis of the history and physical examination alone may not be feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the patient with suspected subacromial bursitis, moderate to severe pain, and marked loss of shoulder motion, a subacromial injection of lidocaine may be a useful diagnostic test. If a local anesthetic injection relieves pain and the examination after injection reveals normal strength and improved range of shoulder motion, subacromial bursitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rotator cuff tendinitis are a likely cause of shoulder pain. In contrast, pain relief but with persistent supraspinatus muscle weakness suggests a clinically significant rotator cuff tear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H48#H48\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Lidocaine injection test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of subacromial bursitis includes immobilization with a sling and NSAIDs. If the pain is still disabling after 72 hours, we inject the bursa (",
"    <a class=\"graphic graphic_figure graphicRef60759 \" href=\"UTD.htm?16/24/16783\">",
"     figure 2",
"    </a>",
"    ). The author typically uses 40 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    acetate with 1 percent lidocaine hydrochloride in this area; a 1.5 inch 20 or 22 gauge needle may be necessary.",
"   </p>",
"   <p>",
"    Limited data suggest that ultrasonographically-guided injection of the subacromial bursa may be more effective than \"blind\" injection. However, further study of this approach is necessary to assess whether the additional improvement (70 versus 29 degrees of increased shoulder abduction, respectively, in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/13\">",
"     13",
"    </a>",
"    ]) justifies the additional cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Scapulothoracic bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scapulothoracic bursitis, also referred to as \"painful scapulothoracic articulation\", results from the mechanical pressure and friction between the superior-medial angle of the scapula and the adjacent second and third ribs. Pain and a popping sensation with scapulothoracic motion are typical complaints. Aggravating activities include repetitive movements such as working overhead, reaching up and forward, or doing pushups. Palpable crepitus with motion and local tenderness are suggestive findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H24#H24\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Scapulothoracic bursitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The structures of the scapulothoracic articulation can be divided into superficial, intermediate, and deep layers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superficial layer consists of the trapezius, latissimus dorsi, and an inconsistent bursa between the inferior angle of the scapula and the latissimus dorsi.",
"     </li>",
"     <li>",
"      The intermediate layer consists of the levator scapulae, rhomboid minor and major, spinal accessory nerve, and scapulotrapezial bursa located between the superomedial scapula and the overlying trapezius. The spinal accessory nerve travels intimately along the wall of the scapulotrapezial bursa, an average of 2.7 cm lateral to the superomedial angle of the scapula.",
"     </li>",
"     <li>",
"      The deep layer consists of the serratus anterior, subscapularis, and two bursae: one between the serratus and the thorax, the scapulothoracic bursa; and one between the subscapularis and the serratus, the subscapularis bursa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subscapular bursal effusion may rarely present as a chest wall soft tissue swelling. Hemorrhage into the scapulothoracic bursa may present as a painless palpable mass below the scapula [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/15\">",
"     15",
"    </a>",
"    ]. When imaged using MRI, it appears as a well-demarcated cystic mass between the serratus anterior muscle and the chest wall. In a series of nine patients with scapulothoracic bursal swelling, all regressed spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial conservative approach to treatment includes referral to a physical or occupational therapist for instruction in postural and scapular strengthening exercises and the application of appropriate therapeutic modalities (eg, heat, ultrasound, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/16\">",
"     16",
"    </a>",
"    ]. If physical therapy does not relieve symptoms after several weeks, then fluoroscopically assisted injection of the scapulothoracic bursa may be an option [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/17\">",
"     17",
"    </a>",
"    ]. However, any injection of the upper chest wall structures may cause a pneumothorax",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nerve injury. The presence of bone spurs arising from the scapula or other skeletal abnormalities would favor a surgical approach.",
"   </p>",
"   <p>",
"    For patients with painful subscapular bursitis, we suggest an initial conservative approach consisting of exercise and physical modalities. For patients who do not get sufficient relief from conservative therapy who may require a procedure and are willing to consider operative intervention, we suggest orthopaedic referral.",
"   </p>",
"   <p>",
"    Surgical resection of the bursa and a portion of the scapula may provide relief. This was illustrated in one uncontrolled series of 16 patients that reported the results of various surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/18\">",
"     18",
"    </a>",
"    ]. Resections of the scapulothoracic bursa and excision of the superomedial portion of the scapula were performed arthroscopically, using an open surgical procedure, or a combined arthroscopic and open approach. A \"satisfactory\" result was noted in 81 percent. There were no apparent differences in the effectiveness of the various surgical approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Olecranon bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The olecranon bursa, at the posterior point of the elbow, has a synovial membrane that may be affected by gout, rheumatoid arthritis, sepsis, hemorrhage, or trauma. Swelling of the bursa occurs easily and is readily visible due to its superficial position over the olecranon (",
"    <a class=\"graphic graphic_picture graphicRef64359 \" href=\"UTD.htm?5/0/5121\">",
"     picture 1",
"    </a>",
"    ). Aggravating factors of olecranon bursitis are infection, trauma, gout, and other systemic diseases, such as rheumatoid arthritis. Infection of the bursa usually follows an abrasion or in association with cellulitis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Septic bursitis'",
"    </a>",
"    above.) Traumatic bursitis occurs from pressure. Common causes include leaning on the elbow or using the elbow to arise from bed or as part of an occupation such as laying carpet. The onset is seldom acute when trauma is the inciting cause, and the surrounding tissues are usually normal.",
"   </p>",
"   <p>",
"    Traumatic bursitis is managed as noted above with instruction in joint protection, aspiration of the bursal fluid for culture and analysis, and antiinflammatory agents (see",
"    <a class=\"local\" href=\"#H10\">",
"     'General principles of management'",
"    </a>",
"    above). Resolution is usually within a few weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid injection appears to be more effective than oral NSAIDs in preventing recurrence of olecranon bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Glucocorticoid injection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Chronic persistent olecranon bursitis, often with a rubbery thick synovium, should be considered for surgical removal; this may be performed endoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/19\">",
"     19",
"    </a>",
"    ]. The success of surgery in this setting may vary with the underlying disorder. A review of the surgical experience at the Mayo Clinic found good or excellent results in 15 of 16 patients with intractable nonseptic olecranon bursitis not associated with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/20\">",
"     20",
"    </a>",
"    ]; by comparison, only 2 of 5 patients with rheumatoid arthritis experienced significant benefits with surgery.",
"   </p>",
"   <p>",
"    If septic bursitis has been excluded by aspiration, and pain has not resolved or fluid reaccumulates, we recommend an injection of a mixture of a glucocorticoid and local anesthetic. For the patient who has recurrent or chronic nonseptic olecranon bursitis despite repeated aspiration and injection of glucocorticoids, and is willing to consider a surgical approach we recommend an orthopedic referral for excision of the bursa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ischial (ischiogluteal) bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the 18 or more bursae in the hip region, the most important are the trochanteric and ischiogluteal bursae. \"Weaver's bottom\" or \"tailor's bottom\" refers to pain in the bursa overlying the ischial prominence; irritation of the sciatic nerve may coexist in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient often has pain when sitting or lying. Point tenderness over the bursa with pain reproduction suggests the diagnosis. Rectal examination for prostate irritation should be considered in patients with atypical symptoms. Other disorders that should be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ankylosing spondylitis or another form of spondyloarthritis causing sacroiliitis can usually be excluded by history and physical examination.",
"     </li>",
"     <li>",
"      Radicular or referred pain &mdash; Nerve compression, invasion, bony spinal or soft tissue lesions can cause radicular or referred pain.",
"     </li>",
"     <li>",
"      Tenosynovitis of the hamstring &mdash; However, the ischium is not the site of tenderness in this condition. Instead, the upper muscular tissue is tender, straight leg raising is painful, and the leg usually cannot be raised beyond 60 degrees.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suggestions for treatment discussed below for ischiogluteal bursitis are based on the author's clinical experience and the limited literature on this topic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/21\">",
"     21",
"    </a>",
"    ]. We suggest a therapeutic trial of an NSAID. If this fails, a local anesthetic-glucocorticoid injection into the site of maximum tenderness should be considered. It is important to advise the patient to be alert for neuritic pain occurring during the injection and to report it immediately, since the sciatic nerve is nearby and should not be injected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/21\">",
"     21",
"    </a>",
"    ]. Bursal injection may be followed by use of a three-inch foam rubber cut-out cushion. The cushion should have two holes cut for the ischial prominences. Each hole should be about three inches in diameter and about three inches apart.",
"   </p>",
"   <p>",
"    Ischial bursitis may be intractable, and can last many months. Stretching and knee to chest exercises should be performing while lying on the cushion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Trochanteric bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep trochanteric bursa lies between the tendon of the gluteus medius and the posterolateral prominence of the greater trochanter. A more superficial bursa directly over the greater trochanter may also become inflamed and tender (",
"    <a class=\"graphic graphic_figure graphicRef60606 \" href=\"UTD.htm?8/53/9042\">",
"     figure 3",
"    </a>",
"    ). Bursitis in this area with characteristic night pain may occur concomitantly with osteoarthritis of the hip. The clinical manifestations, diagnosis, and treatment of trochanteric bursitis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18966?source=see_link\">",
"     \"Trochanteric bursitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prepatellar bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prepatellar bursitis is a common condition that is related to recurrent trauma. It is seen in people who must kneel down frequently (\"housemaid's knee\"). Inflammation overlying the patella is usually evident visually. Although typically secondary to trauma, prepatellar bursitis may also be due to infection or crystalline disease. Thus, aspiration of prepatellar bursal fluid for a white blood cell count and differential, Gram stain, glucose, culture and sensitivity, and crystal identification should be performed when fluid is readily palpable and persistent. The management of septic bursitis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33256?source=see_link\">",
"     \"Septic bursitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of cases of nonseptic prepatellar bursitis resolve with rest and avoidance of continued trauma, although aspiration is occasionally necessary and glucocorticoid injection or surgery may be needed for those who have disease that is refractory to more conservative measures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=see_link&amp;anchor=H2#H2\">",
"     \"Knee bursitis\", section on 'Prepatellar bursitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anserine bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anserine bursitis should be suspected when pain occurs, particularly at night, in the medial knee region over the upper tibia. Repetitive knee flexion such as stair climbing aggravates this disorder. Osteoarthritis is often present and may predispose to bursitis. The clinical manifestations, diagnosis, and treatment of anserine bursitis are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=see_link&amp;anchor=H12#H12\">",
"     \"Knee bursitis\", section on 'Anserine bursitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Retrocalcaneal bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bursae may form superficial or deep to the Achilles tendon. Pain caused by retrocalcaneal bursitis and other lesions in the retrocalcaneal space can be chronic and incapacitating. Although use of NSAIDs and slitting the heel counter of the shoe may help, surgery is sometimes necessary for permanent relief. Glucocorticoid injections of the retrocalcaneal space are not recommended as the steroid may lead to rupture of the Achilles tendon. In one study, comparing 33 patients treated endoscopically with 17 patients treated with open surgery, endoscopic decompression was as successful as open surgery and with fewer complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/22\">",
"     22",
"    </a>",
"    ]. The choice of surgery will depend on the surgeon's experience.",
"   </p>",
"   <p>",
"    Retrocalcaneal bursitis in association with a protuberance of the calcaneus is referred to as Haglund's syndrome. The prominence is typically palpable and apparent on plain radiographs. Haglund's syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=see_link&amp;anchor=H20#H20\">",
"     \"Plantar fasciitis and other causes of heel pain\", section on 'Haglund's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Intermetatarsal bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With aging, the metatarsal arch flattens, and the metatarsal heads become broader and often impinge upon the bursa; tight and narrow shoes contribute to these events. The resulting bursitis gives rise to symptoms similar to a Morton's neuroma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/23\">",
"     23",
"    </a>",
"    ]. Bursitis should be considered if pain can be accentuated by compressing the metatarsal tissue about one inch proximal to the web space between the metatarsal heads. Occasionally thumbnail pressure is necessary. Visible swelling is rare.",
"   </p>",
"   <p>",
"    Management includes use of wider shoes, metatarsal bars (rocker bars) (",
"    <a class=\"graphic graphic_figure graphicRef65017 \" href=\"UTD.htm?41/17/42261\">",
"     figure 4",
"    </a>",
"    ), and intermetatarsal (between the metatarsal heads) injection with a corticosteroid and local anesthetic combination. Application of ice to the area may prevent a reaction to the steroid crystals that is a common consequence of injection in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9690957\">",
"    <span class=\"h2\">",
"     Iliopsoas bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iliopsoas bursitis and tendonitis are associated with anterior hip or groin pain. The iliopsoas bursa, which lies medially in the femoral triangle, is located between the iliopsoas tendon and the lesser trochanter and extends into the iliac fossa beneath the iliacus muscle. The hip joint communicates with the bursa in about ten percent of patients through a defect in the anterior aspect of the joint capsule. Iliopsoas bursitis is often associated with hip pathology due to arthritis, such as rheumatoid arthritis or osteoarthritis; overuse injury, for example from running; or acute trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/24\">",
"     24",
"    </a>",
"    ]. Infection of this bursa is rare, but should be considered in patients who have undergone recent hip injection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain from iliopsoas bursitis radiates down the anteromedial side of the thigh to the knee and is increased on extension, adduction, and internal rotation of the hip. Thus, it may occur with weight-bearing, putting on socks and shoes, or rising from a seated position. Typically, pain worsens slowly over weeks or months and may be the only symptom present. Tenderness may be present anteriorly below the middle of the inguinal ligament and lateral to the femoral artery. Occasionally, a palpable mass or visible edema may be found lateral to the femoral vessels. Pulsations from the femoral artery are sometimes transmitted through this mass. This is increased when the hip is extended and rotated. Retroperitoneal extension may result in an abdominal or pelvic mass that causes compressive syndromes in the groin or pelvis. Radiographs are usually normal; ultrasonography and magnetic resonance imaging may be helpful in diagnosis.",
"   </p>",
"   <p>",
"    Management generally consists of rest, nonsteroidal antiinflammatory drugs, and physical therapy, including stretching, strengthening and local measures. There are no systematic studies of treatment approaches. Some patients benefit from glucocorticoid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/45/14041/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. Surgical excision is generally not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/23/3443?source=see_link\">",
"       \"Patient information: Bursitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"       \"Patient information: Bursitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bursitis refers to inflammation or degeneration of sac-like structures that form between other soft tissues and bony prominences. Bursitis may be a manifestation of a local injury or a systemic disease.",
"     </li>",
"     <li>",
"      Typical clinical features include: pain with motion and rest. The medical history may identify preceding trauma or repetitive injury. In the absence of features of infectious and systemic disorders the physical examination is focused on the painful area. Tenderness over the bursa and, in the case of superficially located bursae (eg, olecranon or prepatellar), other signs of inflammation (ie, erythema and swelling) may be apparent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bursal fluid aspiration is recommended whenever there is a palpable fluid collection and symptoms or signs of inflammation. Fluid is examined for evidence of infection (ie, Gram stain, cell count and differential, culture) and for crystal-induced inflammation (compensated polarized microscopy). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bursal fluid aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Superficial bursitis generally does not require imaging. We suggest use of plain film radiographs in cases of penetrating trauma to exclude foreign bodies. Imaging",
"      <strong>",
"       is",
"      </strong>",
"      necessary for those with suspected deep bursal infection and this typically requires ultrasonography or MRI to assess for bursal swelling, and ultrasound or CT scanning to guide needle aspiration. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection, crystal diseases, and trauma are common causes of bursitis. Bursitis associated with systemic arthritic diseases, such as rheumatoid arthritis, typically presents along with the associated polyarthritis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis of bursitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of nonseptic bursitis includes patient education regarding avoidance of aggravating activities and joint protection techniques. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic interventions (ice, heat, rest) are safe and may help acutely with pain.",
"     </li>",
"     <li>",
"      In the absence of known coronary artery or cerebral vascular disease, anticoagulation, or other comorbidities that preclude use of an NSAID, we suggest use of an antiinflammatory dose of a nonselective NSAID (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The author generally uses indomethacin (75 mg twice daily). However, other NSAIDs and selective COX-2 inhibitors are also effective for nonseptic bursitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'NSAIDs'",
"      </a>",
"      above.) Glucocorticoid injection is an alternative for patients with severe pain, contraindications to the use of NSAIDs but at low risk for septic bursitis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Glucocorticoid injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a glucocorticoid injection for patients with bursitis that persists despite several days of an NSAID (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The author prefers to use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      acetate for soft tissue injections;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      hexacetonide is an alternative. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Glucocorticoid injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More detailed discussions of bursitis in specific locations, including recommendations on management, are presented in the sections above.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/2\">",
"      Ishii H, Brunet JA, Welsh RP, Uhthoff HK. \"Bursal reactions\" in rotator cuff tearing, the impingement syndrome, and calcifying tendinitis. J Shoulder Elbow Surg 1997; 6:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/3\">",
"      Stell IM, Gransden WR. Simple tests for septic bursitis: comparative study. BMJ 1998; 316:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/4\">",
"      Canoso JJ, Yood RA. Reaction of superficial bursae in response to specific disease stimuli. Arthritis Rheum 1979; 22:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/5\">",
"      Dawn B, Williams JK, Walker SE. Prepatellar bursitis: a unique presentation of tophaceous gout in an normouricemic patient. J Rheumatol 1997; 24:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/6\">",
"      Beltran J. MR imaging of soft-tissue infection. Magn Reson Imaging Clin N Am 1995; 3:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/7\">",
"      Garcia GM, McCord GC, Kumar R. Hydroxyapatite crystal deposition disease. Semin Musculoskelet Radiol 2003; 7:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/8\">",
"      Molloy ES, McCarthy GM. Calcium crystal deposition diseases: update on pathogenesis and manifestations. Rheum Dis Clin North Am 2006; 32:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/9\">",
"      Petri M, Hufman SL, Waser G, et al. Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis. J Rheumatol 2004; 31:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/10\">",
"      Smith DL, McAfee JH, Lucas LM, et al. Treatment of nonseptic olecranon bursitis. A controlled, blinded prospective trial. Arch Intern Med 1989; 149:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/11\">",
"      Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003; :CD004016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/12\">",
"      Mens JM, Nico de Wolf A, Berkhout BJ, Stam HJ. Disturbance of the menstrual pattern after local injection with triamcinolone acetonide. Ann Rheum Dis 1998; 57:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/13\">",
"      Chen MJ, Lew HL, Hsu TC, et al. Ultrasound-guided shoulder injections in the treatment of subacromial bursitis. Am J Phys Med Rehabil 2006; 85:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/14\">",
"      Williams GR Jr, Shakil M, Klimkiewicz J, Iannotti JP. Anatomy of the scapulothoracic articulation. Clin Orthop Relat Res 1999; :237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/15\">",
"      Higuchi T, Ogose A, Hotta T, et al. Clinical and imaging features of distended scapulothoracic bursitis: spontaneously regressed pseudotumoral lesion. J Comput Assist Tomogr 2004; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/16\">",
"      Kuhn JE, Plancher KD, Hawkins RJ. Symptomatic scapulothoracic crepitus and bursitis. J Am Acad Orthop Surg 1998; 6:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/17\">",
"      Hodler J, Gilula LA, Ditsios KT, Yamaguchi K. Fluoroscopically guided scapulothoracic injections. AJR Am J Roentgenol 2003; 181:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/18\">",
"      Lehtinen JT, Macy JC, Cassinelli E, Warner JJ. The painful scapulothoracic articulation: surgical management. Clin Orthop Relat Res 2004; :99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/19\">",
"      Kerr DR, Carpenter CW. Arthroscopic resection of olecranon and prepatellar bursae. Arthroscopy 1990; 6:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/20\">",
"      Stewart NJ, Manzanares JB, Morrey BF. Surgical treatment of aseptic olecranon bursitis. J Shoulder Elbow Surg 1997; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/21\">",
"      Swartout R, Compere EL. Ischiogluteal bursitis. The pain in the arse. JAMA 1974; 227:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/22\">",
"      Leitze Z, Sella EJ, Aversa JM. Endoscopic decompression of the retrocalcaneal space. J Bone Joint Surg Am 2003; 85-A:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/23\">",
"      Bossley CJ, Cairney PC. The intermetatarsophalangeal bursa--its significance in Morton's metatarsalgia. J Bone Joint Surg Br 1980; 62-B:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/24\">",
"      Johnston CA, Wiley JP, Lindsay DM, Wiseman DA. Iliopsoas bursitis and tendinitis. A review. Sports Med 1998; 25:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/25\">",
"      Toohey AK, LaSalle TL, Martinez S, Polisson RP. Iliopsoas bursitis: clinical features, radiographic findings, and disease associations. Semin Arthritis Rheum 1990; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/45/14041/abstract/26\">",
"      Parziale JR, O'Donnell CJ, Sandman DN. Iliopsoas bursitis. Am J Phys Med Rehabil 2009; 88:690.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7756 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14041=[""].join("\n");
var outline_f13_45_14041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bursal fluid aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis of bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Septic bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL PRINCIPLES OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Joint protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pain relief",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Glucocorticoid injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SPECIFIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Subacromial bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Scapulothoracic bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Olecranon bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ischial (ischiogluteal) bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Trochanteric bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prepatellar bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anserine bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Retrocalcaneal bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Intermetatarsal bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9690957\">",
"      Iliopsoas bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7756|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/20/33093\" title=\"figure 1\">",
"      Shoulder anatomy anterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/24/16783\" title=\"figure 2\">",
"      Subacromial bursa injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/53/9042\" title=\"figure 3\">",
"      Trochanteric bursa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42261\" title=\"figure 4\">",
"      Shoe modifications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7756|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/0/5121\" title=\"picture 1\">",
"      Olecranon bursitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=related_link\">",
"      Joint protection program for the lower limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37508?source=related_link\">",
"      Joint protection program for the upper limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=related_link\">",
"      Knee bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=related_link\">",
"      Musculoskeletal ultrasonography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=related_link\">",
"      Overview of soft tissue rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=related_link\">",
"      Patient information: Bursitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/23/3443?source=related_link\">",
"      Patient information: Bursitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=related_link\">",
"      Plantar fasciitis and other causes of heel pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33256?source=related_link\">",
"      Septic bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18966?source=related_link\">",
"      Trochanteric bursitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_45_14042="Dexamethasone (systemic): Drug information";
var content_f13_45_14042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexamethasone (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=see_link\">",
"    see \"Dexamethasone (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/18/6442?source=see_link\">",
"    see \"Dexamethasone (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8015648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Baycadron&trade;;",
"     </li>",
"     <li>",
"      Dexamethasone Intensol&trade;;",
"     </li>",
"     <li>",
"      DexPak&reg; 10 Day TaperPak&reg;;",
"     </li>",
"     <li>",
"      DexPak&reg; 13 Day TaperPak&reg;;",
"     </li>",
"     <li>",
"      DexPak&reg; 6 Day TaperPak&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8015649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dexamethasone&reg;;",
"     </li>",
"     <li>",
"      Dexasone&reg;;",
"     </li>",
"     <li>",
"      Dom-Dexamethasone;",
"     </li>",
"     <li>",
"      PHL-Dexamethasone;",
"     </li>",
"     <li>",
"      PMS-Dexamethasone;",
"     </li>",
"     <li>",
"      PRO-Dexamethasone;",
"     </li>",
"     <li>",
"      ratio-Dexamethasone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8016759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-inflammatory Agent;",
"     </li>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8015752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral, I.M., I.V.:",
"     </i>",
"     0.75-9 mg/day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intra-articular, intralesional, or soft tissue:",
"     </i>",
"     0.4-6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Extubation or airway edema:",
"     </b>",
"     Oral, I.M., I.V.: 0.5-2 mg/kg/day in divided doses every 6 hours beginning 24 hours prior to extubation and continuing for 4-6 doses afterwards",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"     Oral, I.V.: 10-20 mg 15-30 minutes before treatment on each treatment day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion regimen: Oral or I.V.: 10 mg every 12 hours on each treatment day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mildly emetogenic therapy: Oral, I.M., I.V.: 4 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Delayed nausea/vomiting:",
"     </i>",
"     Oral: 4-10 mg 1-2 times/day for 2-4 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     8 mg every 12 hours for 2 days; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4 mg every 12 hours for 2 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20 mg 1 hour before chemotherapy; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10 mg 12 hours after chemotherapy; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     8 mg every 12 hours for 4 doses; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4 mg every 12 hours for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma:",
"     </b>",
"     Oral, I.V.: 40 mg/day, days 1 to 4, 9 to 12, and 17 to 20, repeated every 4 weeks (alone or as part of a regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cerebral edema:",
"     </b>",
"     I.V. 10 mg stat, 4 mg I.M./I.V. (should be given as sodium phosphate) every 6 hours until response is maximized, then switch to oral regimen, then taper off if appropriate; dosage may be reduced after 2-4 days and gradually discontinued over 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dexamethasone suppression test (depression/suicide indicator) (unlabeled use):",
"     </b>",
"     Oral: 1 mg at 11 PM, draw blood at 8 AM the following day for plasma cortisol determination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cushing's syndrome, diagnostic:",
"     </b>",
"     Oral: 1 mg at 11 PM, draw blood at 8 AM; greater accuracy for Cushing's syndrome may be achieved by the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexamethasone 0.5 mg by mouth every 6 hours for 48 hours (with 24-hour urine collection for 17-hydroxycorticosteroid excretion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Differentiation of Cushing's syndrome due to ACTH excess from Cushing's due to other causes:",
"     </i>",
"     Oral: Dexamethasone 2 mg every 6 hours for 48 hours (with 24-hour urine collection for 17-hydroxycorticosteroid excretion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis (acute exacerbation):",
"     </b>",
"     Oral: 30 mg/day for 1 week, followed by 4-12 mg/day for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of shock:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Addisonian crisis/shock (eg, adrenal insufficiency/responsive to steroid therapy):",
"     </i>",
"     I.V.: 4-10 mg as a single dose, which may be repeated if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unresponsive shock (eg, unresponsive to steroid therapy):",
"     </i>",
"     I.V.: 1-6 mg/kg as a single I.V. dose or up to 40 mg initially followed by repeat doses every 2-6 hours while shock persists",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Physiological replacement:",
"     </b>",
"     Oral, I.M., I.V. (should be given as sodium phosphate): 0.03-0.15 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     0.6-0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute mountain sickness (AMS)/high altitude cerebral edema (HACE) (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Prevention:",
"      </i>",
"     </b>",
"     Oral: 2 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     4 mg every 12 hours starting on the day of ascent; may be discontinued after staying at the same elevation for 2-3 days or if descent is initiated; do not exceed a 10 day duration (Luks, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     In situations of rapid ascent to altitudes &gt;3500 meters (such as rescue or military operations), 4 mg every 6 hours may be considered (Luks, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Treatment:",
"      </i>",
"     </b>",
"     Oral, I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      AMS:",
"     </i>",
"     4 mg every 6 hours (Luks, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      HACE:",
"     </i>",
"     Initial: 8 mg as a single dose; Maintenance: 4 mg every 6 hours until symptoms resolve (Luks, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8015751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/18/6442?source=see_link\">",
"      see \"Dexamethasone (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic (prior to chemotherapy):",
"     </b>",
"     Refer to individual protocols and emetogenic potential: I.V.: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12-24 hours on days of chemotherapy for severely emetogenic chemotherapy courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory and/or immunosuppressant:",
"     </b>",
"     Oral, I.M., I.V.: 0.08-0.3 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     2.5-10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Extubation or airway edema:",
"     </b>",
"     Oral, I.M., I.V.: 0.5-2 mg/kg/day in divided doses every 6 hours beginning 24 hours prior to extubation and continuing for 4-6 doses afterwards",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cerebral edema:",
"     </b>",
"     I.V.: Loading dose: 1-2 mg/kg/dose as a single dose; maintenance: 1-1.5 mg/kg/day (maximum: 16 mg/day) in divided doses every 4-6 hours, taper off over 1-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Croup (laryngotracheobronchitis):",
"     </b>",
"     Oral, I.M., I.V.: 0.6 mg/kg once; usual maximum dose: 16 mg (doses as high as 20 mg have been used) (Bjornson, 2004; Hegenbarth, 2008; Rittichier, 2000); a single oral dose of 0.15 mg/kg has been shown effective in children with mild-to-moderate croup (Russell, 2004; Sparrow, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacterial meningitis:",
"     </b>",
"     Infants and Children &gt;6 weeks: I.V.: 0.15 mg/kg/dose  every 6 hours for the first 2-4 days of antibiotic treatment; start dexamethasone 10-20 minutes before or with the first dose of antibiotic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Physiologic replacement:",
"     </b>",
"     Oral, I.M., I.V.: 0.03-0.15 mg/kg/day or 0.6-0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute mountain sickness (AMS)/high altitude cerebral edema (HACE) (unlabeled use):",
"     </b>",
"     Oral, I.M., I.V.: 0.15 mg/kg/dose every 6 hours; consider using for high altitude pulmonary edema because of associated HACE with this condition (Luks, 2010; Pollard, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8015753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use cautiously in the elderly in the smallest possible dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8015754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution. Hemodialysis or peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15827036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8016329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral: 0.5 mg/5 mL (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baycadron&trade;: 0.5 mg/5 mL (237 mL) [contains benzoic acid, ethanol 5.1%, propylene glycol; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium phosphate: 4 mg/mL (1 mL, 5 mL, 30 mL); 10 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium phosphate [preservative free]: 10 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 0.5 mg/5 mL (240 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexamethasone Intensol&trade;: 1 mg/mL (30 mL) [dye free, sugar free; contains benzoic acid, ethanol 30%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DexPak&reg; 6 Day TaperPak&reg;: 1.5 mg [scored; 21 tablets on taper dose card]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DexPak&reg; 10 Day TaperPak&reg;: 1.5 mg [scored; 35 tablets on taper dose card]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DexPak&reg; 13 Day TaperPak&reg;: 1.5 mg [scored; 51 tablets on taper dose card]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8015651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes concentrated oral solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8016306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with meals to decrease GI upset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer as a 5-10 minute bolus; rapid injection is associated with a high incidence of perineal discomfort.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8015720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, allopurinol, amifostine, amikacin, amphotericin B cholesteryl sulfate complex, amsacrine, anidulafungin, aztreonam, bivalirudin, caffeine citrate, cefepime, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doripenem, doxorubicin, doxorubicin liposome, etoposide phosphate, famotidine, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, gallium nitrate, gemcitabine, granisetron, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactate electrolyte injection (Hextend&reg;), levofloxacin, linezolid, lorazepam, melphalan, meperidine, meropenem, methadone, milrinone, ondansetron, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, sodium bicarbonate, sufentanil, tacrolimus, telavancin, teniposide, theophylline, thiotepa, vinorelbine, vitamin B complex with C, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ciprofloxacin, diphenhydramine, fenoldopam, fosaprepitant, haloperidol, idarubicin, midazolam, pantoprazole, topotecan.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone, methotrexate, metoclopramide, morphine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, dimenhydrinate, droperidol, furosemide, granisetron, ketamine, ketorolac, metoclopramide, palonosetron, ranitidine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, famotidine, glycopyrrolate, pantoprazole, promethazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diphenhydramine, hydromorphone, midazolam, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8015652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily as an anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of  allergic, dermatologic, endocrine, hematologic, inflammatory, neoplastic, nervous system, renal, respiratory, rheumatic, and autoimmune origin; may be used in management of cerebral edema, chronic swelling, as a diagnostic agent, diagnosis of Cushing&rsquo;s syndrome, antiemetic",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8015697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dexamethasone suppression test as an indicator of depression and/or risk of suicide; prevention and treatment of acute mountain sickness and high altitude cerebral edema; accelerate fetal lung maturation in patients with preterm labor",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8015647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexamethasone may be confused with desoximetasone, dextroamphetamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Decadron&reg; may be confused with Percodan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8015707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, cardiomyopathy, CHF, circulatory collapse, edema, hypertension, myocardial rupture (post-MI), syncope, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, emotional instability, euphoria, headache, intracranial pressure increased, insomnia, malaise, mood swings, neuritis, personality changes, pseudotumor cerebri (usually following discontinuation), psychic disorders, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, alopecia, angioedema, bruising, dry skin, erythema, fragile skin, hirsutism, hyper-/hypopigmentation, hypertrichosis, perianal pruritus (following I.V. injection), petechiae, rash, skin atrophy, skin test reaction impaired, striae, urticaria, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, carbohydrate tolerance decreased, Cushing's syndrome, diabetes mellitus, glucose intolerance decreased, growth suppression (children), hyperglycemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary-adrenal axis suppression, protein catabolism, sodium retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, gastrointestinal hemorrhage, gastrointestinal perforation, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Altered (increased or decreased) spermatogenesis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Postinjection flare (intra-articular use), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthropathy, aseptic necrosis (femoral and humoral heads), fractures, muscle mass loss, myopathy (particularly in conjunction with neuromuscular disease or neuromuscular-blocking agents), neuropathy, osteoporosis, parasthesia, tendon rupture, vertebral compression fractures, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmos, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glucosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat deposition, anaphylactoid reaction, anaphylaxis, avascular necrosis, diaphoresis, hiccups, hypersensitivity, impaired wound healing, infections, Kaposi's sarcoma, moon face, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8015703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexamethasone or any component of the formulation; systemic fungal infections, cerebral malaria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8015704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Dexamethasone does not provide adequate mineralocorticoid activity in adrenal insufficiency (may be employed as a single dose while cortisol assays are performed). The lowest possible dose should be used during treatment; discontinuation and/or dose reductions should be gradual.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury: Increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. High-dose corticosteroids should not be used for the management of head injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8015710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (weak/moderate), CYP2B6 (weak/moderate), CYP2C9 (weak/moderate), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8015711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asparaginase (E. coli): May increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asparaginase (Erwinia): May increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Dexamethasone (Systemic) may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Dexamethasone (Systemic) may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lenalidomide: Dexamethasone (Systemic) may enhance the thrombogenic effect of Lenalidomide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Dexamethasone (Systemic) may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thalidomide: Dexamethasone (Systemic) may enhance the dermatologic adverse effect of Thalidomide. Dexamethasone (Systemic) may enhance the thrombogenic effect of Thalidomide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8015715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Dexamethasone interferes with calcium absorption. Limit caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid cat's claw, echinacea (have immunostimulant properties).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8015698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8015699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Dexamethasone crosses the placenta; and is partially metabolized to an inactive metabolite by placental enzymes. Due to its positive effect on stimulating fetal lung maturation, the injection is often used in patients with premature labor (24-34 weeks gestation). Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to dexamethasone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8015701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8015702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids are excreted in human milk; information specific to dexamethasone has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8015756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals to decrease GI upset. May need diet with increased potassium, pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8016331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Dexamethasone Intensol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (30 mL): $23.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Baycadron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/5 mL (237 mL): $79.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Dexamethasone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/5 mL (237 mL): $63.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dexamethasone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/5 mL (240 mL): $63.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dexamethasone Sod Phosphate PF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $3.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dexamethasone Sodium Phosphate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (5 mL): $2.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (10 mL): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dexamethasone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $20.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (100): $36.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $35.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (100): $27.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $68.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $64.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (100): $107.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DexPak 10 Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (35): $44.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DexPak 13 Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (51): $51.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DexPak 6 Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (21): $31.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8016312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin, occult blood loss, serum potassium, glucose, growth in children",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8015723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dexamethasone suppression test, overnight: 8 AM cortisol &lt;6 mcg/100 mL (dexamethasone 1 mg); plasma cortisol determination should be made on the day after giving dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aacidexam (BE);",
"     </li>",
"     <li>",
"      Alin (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      BiDexol (TH);",
"     </li>",
"     <li>",
"      Coenkasu (TW);",
"     </li>",
"     <li>",
"      Cordex (PH);",
"     </li>",
"     <li>",
"      Corodex (UY);",
"     </li>",
"     <li>",
"      Cortidex (ID);",
"     </li>",
"     <li>",
"      Cortidexason (DE);",
"     </li>",
"     <li>",
"      Cortyk (CN);",
"     </li>",
"     <li>",
"      Decadron (AR, BF, BJ, BR, CI, CO, DE, EC, ET, GH, GM, GN, GR, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, PK, PT, PY, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Decadronal (BR);",
"     </li>",
"     <li>",
"      Decan (PH, SG);",
"     </li>",
"     <li>",
"      Decasone (ZA);",
"     </li>",
"     <li>",
"      Decdan (IN);",
"     </li>",
"     <li>",
"      Decilone (PH);",
"     </li>",
"     <li>",
"      Dectancyl (AE, BH, CY, EG, FR, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Demexam (EC);",
"     </li>",
"     <li>",
"      Desalark (IT);",
"     </li>",
"     <li>",
"      Dexacort (PE);",
"     </li>",
"     <li>",
"      Dexacort Forte (IL);",
"     </li>",
"     <li>",
"      Dexacortal (SE);",
"     </li>",
"     <li>",
"      Dexaflam (DE);",
"     </li>",
"     <li>",
"      Dexagel (TH);",
"     </li>",
"     <li>",
"      Dexalocal (CR, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Dexalone (MY);",
"     </li>",
"     <li>",
"      Dexamed (CZ, SG);",
"     </li>",
"     <li>",
"      Dexametason (FI);",
"     </li>",
"     <li>",
"      Dexamethasone (IL, NZ);",
"     </li>",
"     <li>",
"      Dexamin (VE);",
"     </li>",
"     <li>",
"      Dexano (TH);",
"     </li>",
"     <li>",
"      Dexasolone (KP);",
"     </li>",
"     <li>",
"      Dexasone (HK, TH);",
"     </li>",
"     <li>",
"      Dexazone (TW);",
"     </li>",
"     <li>",
"      Dexmethsone (AU, NZ);",
"     </li>",
"     <li>",
"      Dexona (AE, BH, CY, EG, IN, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fortecortin (AT, BG, CH, CZ, DE, NO, RU);",
"     </li>",
"     <li>",
"      Lodexa (TH);",
"     </li>",
"     <li>",
"      Oftan-Dexa (FI);",
"     </li>",
"     <li>",
"      Onadron (TR);",
"     </li>",
"     <li>",
"      Oradexon (AE, BF, BH, BJ, CI, CN, CY, EG, ET, FI, GH, GM, GN, GR, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PE, PH, PT, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Penatone (MY);",
"     </li>",
"     <li>",
"      Roximeth (MY);",
"     </li>",
"     <li>",
"      Santeson (PH);",
"     </li>",
"     <li>",
"      Spersadex (NO);",
"     </li>",
"     <li>",
"      Supertendin (DE);",
"     </li>",
"     <li>",
"      Thilodexine (GR);",
"     </li>",
"     <li>",
"      Vexamet (PH);",
"     </li>",
"     <li>",
"      Visumetazone (IT);",
"     </li>",
"     <li>",
"      Wymesone (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8015721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response. Dexamethasone's mechanism of antiemetic activity is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8015724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Acetate: Prompt",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of metabolic effect: 72 hours; acetate is a long-acting repository preparation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 1.8-3.5 hours; Biological half-life: 36-54 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 1-2 hours; I.M.: ~8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham E and Evans T, &ldquo;Corticosteroids and Septic Shock [editorial],&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):886-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/12186608/pubmed\" id=\"12186608\" target=\"_blank\">",
"        12186608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Dexamethasone Therapy for Bacterial Meningitis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(1):130-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/2193301/pubmed\" id=\"2193301\" target=\"_blank\">",
"        2193301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion No. 402: Antenatal Corticosteroid Therapy for Fetal Maturation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(3):805-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/18310392/pubmed\" id=\"18310392\" target=\"_blank\">",
"        18310392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):862-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/12186604/pubmed\" id=\"12186604\" target=\"_blank\">",
"        12186604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahal N and Nahata MC, &ldquo;The Role of Corticosteroids in Infants and Children With Bacterial Meningitis,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(5):542-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/2068839/pubmed\" id=\"2068839\" target=\"_blank\">",
"        2068839",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bjornson CL, Klassen TP, Williamson J, et al, \"A Randomized Trial of a Single Dose of Oral Dexamethasone for Mild Croup,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(13):1306-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/15385657/pubmed\" id=\"15385657\" target=\"_blank\">",
"        15385657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. XV. Steroids,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):91-5",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/17511554/pubmed\" id=\"17511554\" target=\"_blank\">",
"        17511554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/12594318/pubmed\" id=\"12594318\" target=\"_blank\">",
"        12594318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coryell WH, &ldquo;Clinical Assessment of Suicide Risk in Depressive Disorder,&rdquo;",
"      <i>",
"       CNS Spectr",
"      </i>",
"      , 2006, 11(6):455-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/16816777/pubmed\" id=\"16816777\" target=\"_blank\">",
"        16816777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(2):236-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/11779267/pubmed\" id=\"11779267\" target=\"_blank\">",
"        11779267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Couser RJ, Ferrara TB, Falde B, et al, &ldquo;Effectiveness of Dexamethasone in Preventing Extubation Failure in Preterm Infants at Increased Risk for Airway Edema,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(4):591-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/1403397/pubmed\" id=\"1403397\" target=\"_blank\">",
"        1403397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jonghe B, Sharshar T, Lefaucheur JP, et al, &ldquo;Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(22):2859-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/12472328/pubmed\" id=\"12472328\" target=\"_blank\">",
"        12472328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting During Chemotherapy for Cancer. The Italian Group for Antiemetic Research,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(1):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/7990859/pubmed\" id=\"7990859\" target=\"_blank\">",
"        7990859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duggan DE, Matalia N, Ditzler, CA, et al, &ldquo;Bioavailability of Oral Dexamethasone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1975, 18(2):205-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/1097154/pubmed\" id=\"1097154\" target=\"_blank\">",
"        1097154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durand M, Sardesai S, and McEvoy C, &ldquo;Effects of Early Dexamethasone Therapy on Pulmonary Mechanics and Chronic Lung Disease in Very Low Birth Weight Infants: A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(4):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/7700763/pubmed\" id=\"7700763\" target=\"_blank\">",
"        7700763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards P, Arango M, Balica L, et al, &ldquo;Final Results of MRC Crash, A Randomized Placebo-Controlled Trial of Intravenous Corticosteroid in Adults With Head Injury &ndash; Outcomes at 6 Months,&rdquo;",
"      <i>",
"       Lancet,",
"      </i>",
"      2005, 365(9475):1957-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/15936423/pubmed\" id=\"15936423\" target=\"_blank\">",
"        15936423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kris MG, Baltzer L, Pisters KM, et al, &ldquo;Enhancing the Effectiveness of the Specific Serotonin Antagonists. Combination Antiemetic Therapy With Dexamethasone,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1993, 72(11 Suppl):3436-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/8242576/pubmed\" id=\"8242576\" target=\"_blank\">",
"        8242576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kyle RA and Rajkumar SV, &ldquo;Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(18): 1860-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/15575057/pubmed\" id=\"15575057\" target=\"_blank\">",
"        15575057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Latreille J, Stewart D, Laberge F, et al, &ldquo;Dexamethasone Improves the Efficacy of Granisetron in the First 24 h Following High-Dose Cisplatin Chemotherapy,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 1995, 3(5):307-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/8520877/pubmed\" id=\"8520877\" target=\"_blank\">",
"        8520877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luks AM, McIntosh SE, Grissom CK, et al, &ldquo;Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,&rdquo;",
"      <i>",
"       Wilderness Environ Med",
"      </i>",
"      , 2010, 21(2):146-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/20591379/pubmed\" id=\"20591379\" target=\"_blank\">",
"        20591379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mann JJ, Currier D, Stanley B, et al, &ldquo;Can Biological Tests Assist Prediction of Suicide in Mood Disorders?&rdquo;",
"      <i>",
"       Int J Neuropsychopharmacol",
"      </i>",
"      , 2006, 9(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/15967058/pubmed\" id=\"15967058\" target=\"_blank\">",
"        15967058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, Pastores SM, Annane D, et al, &ldquo;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(6):1937-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/18496365/pubmed\" id=\"18496365\" target=\"_blank\">",
"        18496365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonnell M and Evans N, &ldquo;Upper and Lower Gastrointestinal Complications With Dexamethasone Despite H2 Antagonists,&rdquo;",
"      <i>",
"       J Paediatr Child Health",
"      </i>",
"      , 1995, 31(2):152-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/7794619/pubmed\" id=\"7794619\" target=\"_blank\">",
"        7794619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng PC, &ldquo;The Effectiveness and Side Effects of Dexamethasone in Preterm Infants With Bronchopulmonary Dysplasia,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1993, 68(3 Spec No):330-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/8466274/pubmed\" id=\"8466274\" target=\"_blank\">",
"        8466274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peterson C, Hursti TJ, Borjeson S, et al, &ldquo;Single High-Dose Dexamethasone Improves the Effect of Ondansetron on Acute Chemotherapy-Induced Nausea and Vomiting But Impairs the Control of Delayed Symptoms,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 1996, 4(6):440-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/8961475/pubmed\" id=\"8961475\" target=\"_blank\">",
"        8961475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollard AJ, Niermeyer S, Barry P, et al, &ldquo;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&rdquo;",
"      <i>",
"       High Alt Med Biol",
"      </i>",
"      , 2001, 2(3):389-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/11682018/pubmed\" id=\"11682018\" target=\"_blank\">",
"        11682018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rittichier KK and Ledwith CA, \"Outpatient Treatment of Moderate Croup With Dexamethasone: Intramuscular Versus Oral Dosing,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(6):1344-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/11099587/pubmed\" id=\"11099587\" target=\"_blank\">",
"        11099587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts I, Yates D, Sandercock P, et al, &ldquo;Effect of Intravenous Corticosteroids on Death Within 14 days in 10,008 Adults With Clinically Significant Head Injury (MRC CRASH trial): Randomised Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2004, 364(9442):1321-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/15474134/pubmed\" id=\"15474134\" target=\"_blank\">",
"        15474134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russell K, Wiebe N, Saenz A, et al, \"Glucocorticoids for Croup,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2004, (1):CD001955.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/14973975/pubmed\" id=\"14973975\" target=\"_blank\">",
"        14973975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruvinsky ED, Douvas SG, Roberts WE, et al, &ldquo;Maternal Administration of Dexamethasone in Severe Pregnancy-Induced Hypertension,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1984, 149(7):722-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/6465221/pubmed\" id=\"6465221\" target=\"_blank\">",
"        6465221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salem M, Tainsh RE Jr, Bromberg J, et al, &ldquo;Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,&rdquo;",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 1994, 219(4):416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/8161268/pubmed\" id=\"8161268\" target=\"_blank\">",
"        8161268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sparrow A and Geelhoed G, \"Prednisolone Versus Dexamethasone in Croup: A Randomised Equivalence Trial,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2006, 91(7):580-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/16624882/pubmed\" id=\"16624882\" target=\"_blank\">",
"        16624882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sprung CL, Annane D, Keh D, et al, &ldquo;Hydrocortisone Therapy for Patients With Septic Shock,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(2):111-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/18184957/pubmed\" id=\"18184957\" target=\"_blank\">",
"        18184957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA and Zhang Y, &ldquo;Compatibility and Stability of Aloxi (Palonosetron Hydrochloride) Admixed With Dexamethasone Sodium Phosphate,&rdquo;",
"      <i>",
"       Intl J Pharm Compounding",
"      </i>",
"      , 2004, 8(5):398-403.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wald ER, Kaplan SL, and Mason, EO Jr, &ldquo;Dexamethasone Therapy for Children With Bacterial Meningitis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(1):21-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/7770303/pubmed\" id=\"7770303\" target=\"_blank\">",
"        7770303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yerevanian BI, Feusner JD, Koek RJ, et al, &ldquo;The Dexamethasone Suppression Test as a Predictor of Suicidal Behavior in Unipolar Depression,&rdquo;",
"      <i>",
"       J Affect Disord",
"      </i>",
"      , 2004, 83(2-3):103-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/45/14042/abstract-text/15555702/pubmed\" id=\"15555702\" target=\"_blank\">",
"        15555702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9100 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14042=[""].join("\n");
var outline_f13_45_14042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015648\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015649\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016759\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015752\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015751\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015753\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015754\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827036\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016329\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015651\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016306\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015720\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015652\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015697\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015647\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015707\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015703\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015704\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015710\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015711\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015715\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015698\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015699\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015701\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015702\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015756\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016331\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016312\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015723\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961968\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015721\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015724\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9100|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/997?source=related_link\">",
"      Dexamethasone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17172?source=related_link\">",
"      Dexamethasone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/51/5941?source=related_link\">",
"      Dexamethasone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=related_link\">",
"      Dexamethasone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/18/6442?source=related_link\">",
"      Dexamethasone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_45_14043="Violence screening questions";
var content_f13_45_14043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Violence victimization screening questions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Have you been hit or harmed by anybody in the last year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you ever been the victim of serious physical violence (defined as physical harm by another person?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If yes, please answer the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Is the violence ongoing?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        How badly were you hurt? (Was an emergency department visit or medical attention necessary?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Who did this to you? Do you know them or are you related?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        What precipitated the event?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Is this likely to recur?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Were alcohol or drugs involved (used, sold)?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jones, RF, Obstet Gynecol 1993; 81:1 and Conway, T, Hu, TC, Kim, P, Bullon, A, J Gen Intern Med 1994; 9:430.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14043=[""].join("\n");
var outline_f13_45_14043=null;
var title_f13_45_14044="WHO dehydration";
var content_f13_45_14044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical signs and symptoms of dehydration in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        No dehydration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Some dehydration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe dehydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Condition*",
"       </td>",
"       <td>",
"        Well, alert",
"       </td>",
"       <td>",
"        Restless, irritable",
"       </td>",
"       <td>",
"        Lethargic or unconscious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes&bull;",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Sunken",
"       </td>",
"       <td>",
"        Very sunken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tears",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mouth and tongue&Delta;",
"       </td>",
"       <td>",
"        Moist",
"       </td>",
"       <td>",
"        Dry",
"       </td>",
"       <td>",
"        Very dry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thirst",
"       </td>",
"       <td>",
"        Drinks normally, not thirsty",
"       </td>",
"       <td>",
"        Thirsty, drinks eagerly",
"       </td>",
"       <td>",
"        Drinks poorly, or not able to drink",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin&loz;",
"       </td>",
"       <td>",
"        Springs back quickly",
"       </td>",
"       <td>",
"        Goes back slowly",
"       </td>",
"       <td>",
"        Goes back very slowly",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Being lethargic and sleepy are not the same. A lethargic child is not simply asleep: the child's mental state is dull and the child cannot be fully awakened; the child may appear to be drifting into unconsciousness.",
"     <br>",
"      &bull; In some infants and children, the eyes normally appear somewhat sunken. It is helpful to ask the mother if the child's eyes are normal or more sunken than usual.",
"      <br>",
"       &Delta; It is necessary to look inside the child's mouth. The mouth may be dry in a child who habitually breathes through the mouth. The mouth may be wet in a dehydrated child owing to recent vomiting or drinking.",
"       <br>",
"        &loz; The skin turgor, as estimated by pinch, is less useful in infants or children with marasmus or kwashiorkor.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reproduced with permission from: Treatment of diarrhea: A manual for physicians and other senior health workers. World Health Organization, Geneva, 2005. Copyright &copy; 2005 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14044=[""].join("\n");
var outline_f13_45_14044=null;
var title_f13_45_14045="Pathogenesis diab neuropathy";
var content_f13_45_14045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential mechanisms linking metbolic, vascular, and neural defects in diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Initiator",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolic defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolic mediator",
"       </td>",
"       <td class=\"subtitle1\">",
"        Functional mediator",
"       </td>",
"       <td class=\"subtitle1\">",
"        Consequence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"12\">",
"        &uarr; Glucose",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Glycation/AGE",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Protein cross-linking",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Matrix defects",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Endoneurial fibrosis",
"        </p>",
"        <p>",
"         &darr; Neurotrophic SAM",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein inactivation",
"       </td>",
"       <td>",
"        Receptor-ligand defects",
"       </td>",
"       <td>",
"        &darr; Neurotrophism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NO quenching",
"       </td>",
"       <td>",
"        Vasoconstriction",
"       </td>",
"       <td colspan=\"1\">",
"        Ischemia/hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Macrophage activation",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Cytokines, &uarr; TGF",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Cytotoxicity*",
"        </p>",
"        <p>",
"         Endoneurial fibrosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Free radical formation",
"       </td>",
"       <td>",
"        Oxidative stress",
"       </td>",
"       <td>",
"        Cytotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autooxidation",
"       </td>",
"       <td>",
"        Free radical formation",
"       </td>",
"       <td>",
"        Oxidative stress",
"       </td>",
"       <td>",
"        Cytotoxicity*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        &uarr; Sorbitol pathway",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &darr; NADPH",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Oxidative stress&darr;",
"        </p>",
"        <p>",
"         NO synthesis",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Cytotoxicity*",
"        </p>",
"        <p>",
"         Ischemia/hypoxia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NADH/lactate",
"       </td>",
"       <td>",
"        Pseudohypoxia",
"       </td>",
"       <td>",
"        Cytotoxicity*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &uarr; Glycation",
"       </td>",
"       <td>",
"        (see above)",
"       </td>",
"       <td>",
"        (see above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &darr; Taurine",
"       </td>",
"       <td>",
"        Oxidative stress",
"       </td>",
"       <td>",
"        Cytotoxicity*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &darr; MI/&darr;",
"PI/&darr;",
"PKC",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Signal transduction",
"        <p>",
"         Eicosinoid defects",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &darr; Neurotrophism",
"        <p>",
"         Ischemia/hypoxia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &uarr; DAG",
"       </td>",
"       <td>",
"        &uarr; PKC",
"       </td>",
"       <td>",
"        Signal transduction",
"       </td>",
"       <td>",
"        Ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        FA defects",
"       </td>",
"       <td>",
"        &uarr; free FA",
"       </td>",
"       <td>",
"        &uarr; long-chain acyl-Co's",
"       </td>",
"       <td>",
"        Mitochondrial defects",
"       </td>",
"       <td>",
"        Cytotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &darr; 3-&beta;-dehydrog.",
"       </td>",
"       <td>",
"        &darr; GLA",
"       </td>",
"       <td>",
"        Eicosinoid defects",
"       </td>",
"       <td colspan=\"1\">",
"        Ischemia/hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &darr; Insulin",
"       </td>",
"       <td>",
"        ?&darr; GF expression",
"       </td>",
"       <td>",
"        ?IGF/NGF/BDNF/NT3",
"       </td>",
"       <td>",
"        Neurotrophic factors",
"       </td>",
"       <td>",
"        &darr; Neurotrophism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AGE: advanced glycosylation end-products; BDNF: brain-derived neurotrophic factor; DAG: diacylglycerol; FA: fatty acid; GLA: gamma linoleic acid; IGF: insulin-like growth factors; MI: myoinositol; NO: nitric oxide; PI: phosphoinositides; PKC: protein kinase C; NT3: neurotrophin-3; SAM: substrate adhesion molecules; TGF: transforming growth factor.",
"     <br>",
"      * Cytotoxicity of neural, glial, and vascular components of peripheral nerve.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Stevens, MJ, Feldman, EL, Greene, DA, Diabet Med 1995; 12:566.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14045=[""].join("\n");
var outline_f13_45_14045=null;
var title_f13_45_14046="Contents: Bipolar disorders";
var content_f13_45_14046=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Bipolar disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Bipolar disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43065\">",
"           Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19639\">",
"           Bipolar disorder in adults: Epidemiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/9/27802\">",
"           Bipolar disorder in adults: Maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44088\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/8/38026\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/61/11226\">",
"           Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/34/37417\">",
"           Bipolar disorder in adults: Treating major depression with antidepressants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/52/8009\">",
"           Bipolar disorder in adults: Treating major depression with second-generation antipsychotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27129\">",
"           Bipolar disorder in postpartum women: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/1/5146\">",
"           Bipolar disorder in postpartum women: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/22/38248\">",
"           Bipolar disorder in pregnant women: Treatment of major depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4362\">",
"           Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/24/40329\">",
"           Bipolar disorder in women: Contraception and preconception assessment and counseling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25638\">",
"           Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/51/2874\">",
"           Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16330\">",
"           Geriatric bipolar disorder: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7545\">",
"           Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/4/22601\">",
"           Geriatric bipolar disorder: Maintenance treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/14/42216\">",
"           Rapid cycling bipolar disorder in adults: Treatment of major depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/44/41673\">",
"           Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31497\">",
"           Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-4A8353D8E1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f13_45_14046=[""].join("\n");
var outline_f13_45_14046=null;
var title_f13_45_14047="Flanged mouthpiece for pulmonary function testing";
var content_f13_45_14047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flanged mouthpiece for pulmonary function testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An example of a flanged rubber mouthpiece for pulmonary function testing. For patients with spinal cord injury a flanged mouthpiece can be used for tests of inspiratory muscle strength.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_45_14047=[""].join("\n");
var outline_f13_45_14047=null;
